,	O
the	O
correlation	O
between	O
Egr-1	O
expression	O
and	O
B	O
cell	O
proliferation	O
breaks	O
down	O
when	O
IL-4	B-protein
is	O
added	O
as	O
a	O
co-mitogen	O
to	O
induce	O
B	O
cell	O
proliferation	O
with	O
IgG	B-protein
anti-Ig	I-protein
or	O
submitogenic	O
concentrations	O
of	O
Fab'2	B-protein
anti-Ig	I-protein
.	O
No	O
corresponding	O
increases	O
in	O
Egr-1	O
mRNA	O
levels	O
are	O
observed	O
when	O
IL-4	B-protein
is	O
added	O
.	O
Therefore	O
,	O
IL-4	B-protein
overcomes	O
Fc	O
receptor-mediated	O
inhibition	O
of	O
B	O
cell	O
proliferation	O
without	O
affecting	O
inhibition	O
of	O
Egr-1	O
mRNA	O
induction	O
,	O
as	O
demonstrated	O
earlier	O
for	O
c-myc	O
mRNA	O
in	O
this	O
system	O
.	O
Identification	O
of	O
a	O
novel	O
cyclosporin-sensitive	O
element	O
in	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
promoter	O
.	O
Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
a	O
cytokine	B-protein
with	O
pleiotropic	O
biological	O
effects	O
,	O
is	O
produced	O
by	O
a	O
variety	O
of	O
cell	O
types	O
in	O
response	O
to	O
induction	O
by	O
diverse	O
stimuli	O
.	O
In	O
this	O
paper	O
,	O
TNF-alpha	O
mRNA	O
is	O
shown	O
to	O
be	O
highly	O
induced	O
in	O
a	O
murine	O
T	O
cell	O
clone	O
by	O
stimulation	O
with	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
ligands	O
or	O
by	O
calcium	O
ionophores	O
alone	O
.	O
Induction	O
is	O
rapid	O
,	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
is	O
completely	O
blocked	O
by	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
We	O
have	O
identified	O
a	O
human	O
TNF-alpha	O
promoter	O
element	O
,	O
kappa	O
3	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
calcium-mediated	O
inducibility	O
and	O
CsA	O
sensitivity	O
of	O
the	O
gene	O
.	O
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
an	O
oligonucleotide	O
containing	O
kappa	O
3	O
forms	O
two	O
DNA	O
protein	O
complexes	O
with	O
proteins	O
that	O
are	O
present	O
in	O
extracts	O
from	O
unstimulated	O
T	O
cells	O
.	O
These	O
complexes	O
appear	O
in	O
nuclear	O
extracts	O
only	O
after	O
T	O
cell	O
stimulation	O
.	O
Induction	O
of	O
the	O
inducible	O
nuclear	B-protein
complexes	I-protein
is	O
rapid	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
and	O
blocked	O
by	O
CsA	O
,	O
and	O
thus	O
,	O
exactly	O
parallels	O
the	O
induction	O
of	O
TNF-alpha	O
mRNA	O
by	O
TCR	O
ligands	O
or	O
by	O
calcium	O
ionophore	O
.	O
Our	O
studies	O
indicate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
resembles	O
the	O
preexisting	O
component	O
of	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
.	O
Thus	O
,	O
the	O
TNF-alpha	O
gene	O
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	O
cells	O
and	O
provides	O
a	O
new	O
model	O
system	O
in	O
which	O
to	O
study	O
CsA-sensitive	O
gene	O
induction	O
in	O
activated	O
T	O
cells	O
.	O
Differences	O
in	O
expression	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	O
promyelocytic	O
HL-60	O
cells	O
during	O
differentiation	O
towards	O
macrophages	O
versus	O
granulocytes	O
.	O
Commitment	O
of	O
HL-60	O
cells	O
to	O
macrophage	O
or	O
granulocytic	O
differentiation	O
was	O
achieved	O
by	O
incubation	O
with	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
for	O
30-60	O
min	O
or	O
with	O
dimethyl	O
sulphoxide	O
(	O
DMSO	O
)	O
for	O
24	O
h	O
respectively	O
.	O
The	O
commitment	O
stage	O
towards	O
PMA-induced	O
macrophage	O
differentiation	O
was	O
associated	O
with	O
increases	O
in	O
jun	O
B	O
and	O
c-fos	O
mRNA	O
levels	O
,	O
as	O
well	O
as	O
with	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O
Nevertheless	O
,	O
gel	O
retardation	O
analysis	O
indicated	O
that	O
the	O
AP-1	B-protein
activity	O
detected	O
in	O
untreated	O
cells	O
was	O
drastically	O
reduced	O
during	O
the	O
commitment	O
stage	O
of	O
DMSO-induced	O
HL-60	O
differentiation	O
towards	O
granulocytes	O
.	O
When	O
HL-60	O
cells	O
were	O
treated	O
with	O
sodium	O
butyrate	O
,	O
which	O
induced	O
monocytic	O
differentiation	O
,	O
a	O
remarkable	O
increase	O
in	O
AP-1	O
binding	O
activity	O
was	O
detected	O
.	O
Treatment	O
of	O
HL-60	O
cells	O
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
,	O
another	O
monocytic	O
differentiation	O
agent	O
,	O
induced	O
a	O
weak	O
,	O
but	O
appreciable	O
,	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O
Furthermore	O
,	O
addition	O
of	O
sodium	O
butyrate	O
or	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
to	O
HL-60	O
cells	O
induced	O
the	O
expression	O
of	O
c-fos	O
,	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
proto-oncogenes	O
.	O
In	O
contrast	O
,	O
when	O
HL-60	O
cells	O
were	O
treated	O
with	O
retinoic	O
acid	O
,	O
a	O
granulocytic	O
differentiation	O
inducer	O
,	O
no	O
enhanced	O
AP-1	O
binding	O
activity	O
was	O
observed	O
,	O
and	O
only	O
a	O
weak	O
increase	O
in	O
jun	O
D	O
mRNA	O
level	O
was	O
detected	O
.	O
These	O
data	O
indicate	O
that	O
formation	O
of	O
AP-1	B-protein
is	O
not	O
required	O
for	O
the	O
induction	O
of	O
HL-60	O
differentiation	O
towards	O
granulocytes	O
,	O
whereas	O
induction	O
of	O
monocytic	O
differentiation	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O
The	O
differential	O
expression	O
of	O
AP-1	B-protein
activity	O
may	O
be	O
critical	O
in	O
the	O
differentiation	O
of	O
HL-60	O
cells	O
towards	O
monocytic	O
or	O
granulocytic	O
lineages	O
Glucocorticoid	B-protein
receptors	I-protein
and	O
sensitivity	O
in	O
leukemias	O
.	O
In	O
an	O
attempt	O
to	O
investigate	O
the	O
utility	O
of	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
to	O
predict	O
clinical	O
responsiveness	O
in	O
human	O
leukemias	O
we	O
have	O
studied	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
leukemic	O
cells	O
from	O
46	O
patients	O
and	O
in	O
the	O
lymphocytes	O
from	O
18	O
normal	O
donors	O
.	O
In	O
the	O
normal	O
lymphocytes	O
there	O
were	O
3	O
,	O
875	O
(	O
Median	O
)	O
specific	O
binding	O
sites	O
per	O
cell	O
.	O
The	O
blasts	O
from	O
17	O
patients	O
with	O
ANLL	O
had	O
on	O
average	O
higher	O
levels	O
of	O
binding	B-protein
sites	I-protein
per	O
cell	O
(	O
Median	O
=	O
7	O
,	O
250	O
,	O
range	O
:	O
0	O
to	O
15	O
,	O
295	O
)	O
than	O
the	O
other	O
leukemias	O
.	O
Of	O
the	O
15	O
patients	O
with	O
CLL	O
,	O
six	O
had	O
received	O
glucocorticoid	O
treatment	O
for	O
3	O
to	O
5	O
years	O
.	O
Their	O
lymphocytes	O
had	O
lower	O
number	O
of	O
receptors	O
(	O
Median	O
=	O
2	O
,	O
000	O
)	O
than	O
the	O
other	O
cases	O
which	O
were	O
newly	O
diagnosed	O
(	O
Median	O
=	O
4	O
,	O
500	O
)	O
.	O
Four	O
patients	O
had	O
ALL/AUL	O
,	O
three	O
patients	O
had	O
blast	O
crisis	O
as	O
terminal	O
phase	O
of	O
CML	O
,	O
and	O
seven	O
had	O
leukemic	O
Non-Hodgkin	O
lymphomas	O
(	O
Median	O
=	O
3	O
,	O
500	O
sites/cell	O
)	O
.	O
In	O
24	O
patients	O
we	O
have	O
also	O
studied	O
the	O
in	O
vitro	O
sensitivity	O
of	O
the	O
leukemic	O
cells	O
to	O
dexamethasone	O
.	O
There	O
was	O
no	O
marked	O
correlation	O
between	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
in	O
vitro	O
sensitivity	O
.	O
An	O
attempt	O
to	O
correlate	O
receptor	O
levels	O
with	O
clinical	O
responsiveness	O
demonstrated	O
that	O
glucocorticoid	B-protein
receptor	I-protein
determination	O
might	O
be	O
of	O
value	O
in	O
patients	O
with	O
lymphoid	O
malignancies	O
but	O
probably	O
not	O
in	O
patients	O
with	O
other	O
leukemias	O
.	O
'Activation-labile	B-protein
'	I-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
of	O
a	O
steroid-resistant	O
variant	O
of	O
CEM-C7	O
human	O
lymphoid	O
cells	O
.	O
For	O
cytoplasmic	B-protein
glucocorticoid-receptor	I-protein
complexes	I-protein
to	O
enter	O
and	O
accumulate	O
in	O
the	O
nucleus	O
a	O
temperature-dependent	O
event	O
,	O
'activation	O
'	O
is	O
required	O
.	O
Activation	O
can	O
be	O
achieved	O
in	O
vitro	O
by	O
increased	O
ionic	O
strength	O
,	O
dilution	O
or	O
gel	O
filtration	O
and	O
is	O
manifested	O
by	O
an	O
increased	O
affinity	O
of	O
steroid-receptor	B-protein
complex	I-protein
for	O
DNA	O
and	O
an	O
altered	O
elution	O
profile	O
from	O
ion-exchange	O
resins	O
.	O
Munck	O
and	O
Foley	O
have	O
shown	O
that	O
activated	B-protein
complexes	I-protein
isolated	O
from	O
thymocytes	O
elute	O
from	O
DEAE-cellulose	O
in	O
a	O
manner	O
identical	O
to	O
complexes	O
activated	O
in	O
vitro	O
.	O
We	O
report	O
here	O
that	O
DEAE-cellulose	O
chromatography	O
of	O
steroid-receptor	B-protein
complexes	I-protein
from	O
CEM-C7	O
,	O
a	O
cloned	O
human	O
leukaemic	O
T-cell	O
line	O
sensitive	O
to	O
the	O
cytolytic	O
action	O
of	O
glucocorticoids	O
,	O
and	O
its	O
steroid-resistant	O
subclone	O
4R4	O
demonstrated	O
that	O
steroid	B-protein
receptors	I-protein
of	O
clone	O
4R4	O
can	O
not	O
form	O
stable	O
activated	O
complexes	O
.	O
This	O
defines	O
a	O
new	O
defect	O
in	O
receptor	O
action	O
,	O
activation	O
lability	O
(	O
r+act1	O
)	O
,	O
which	O
is	O
unlike	O
either	O
the	O
r-	O
,	O
r+nt-	O
,	O
or	O
r+nti	O
phenotypes	O
previously	O
described	O
for	O
mouse	O
lymphoid	O
variants	O
.	O
Granulocytes	O
in	O
the	O
endometrium	O
of	O
post-partum	O
women	O
.	O
Endometrial	O
samples	O
of	O
women	O
at	O
various	O
stages	O
of	O
gonadal	O
activity	O
after	O
parturition	O
were	O
examined	O
for	O
the	O
presence	O
and	O
numbers	O
of	O
endometrial	O
granulocytes	O
.	O
Although	O
samples	O
at	O
all	O
the	O
stages	O
contained	O
significant	O
numbers	O
of	O
the	O
granulocytes	O
(	O
greater	O
than	O
7/high-power	O
field	O
)	O
,	O
the	O
100	O
%	O
values	O
for	O
late-proliferative	O
and	O
adaptation	O
hyperplasia	O
were	O
significantly	O
higher	O
than	O
the	O
values	O
for	O
the	O
resting	O
(	O
81.8	O
%	O
)	O
,	O
early	O
(	O
82.4	O
%	O
)	O
and	O
mid-	O
(	O
87.9	O
%	O
)	O
proliferative	O
and	O
secretory	O
(	O
83.3	O
%	O
)	O
phases	O
.	O
We	O
suggest	O
that	O
this	O
correlates	O
with	O
the	O
suggestion	O
that	O
the	O
granulocytes	O
constitute	O
a	O
receptor	O
system	O
for	O
oestrogens	O
.	O
Interaction	O
of	O
glucocorticoids	O
with	O
macrophages	O
.	O
Identification	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
monocytes	O
and	O
macrophages	O
.	O
Glucocorticoid	O
binding	O
was	O
measured	O
in	O
resident	O
and	O
thioglycollate-elicited	O
mouse	O
peritoneal	O
macrophages	O
,	O
rabbit	O
alveolar	O
macrophages	O
,	O
and	O
human	O
monocytes	O
.	O
Two	O
assays	O
of	O
binding	O
were	O
used	O
--	O
an	O
assay	O
with	O
intact	O
cells	O
in	O
suspension	O
or	O
monolayers	O
,	O
and	O
an	O
assay	O
of	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O
The	O
mononuclear	O
phagocytes	O
contained	O
approximately	O
equal	O
to	O
4	O
--	O
10	O
X	O
10	O
(	O
3	O
)	O
high	B-protein
affinity	I-protein
receptor	I-protein
sites	I-protein
per	O
cell	O
,	O
with	O
dissociation	O
constants	O
of	O
approximately	O
equal	O
to	O
2	O
--	O
8	O
nM	O
dexamethasone	O
.	O
The	O
binding	O
to	O
the	O
saturable	B-protein
sites	I-protein
was	O
specific	O
for	O
steroids	O
with	O
glucocorticoid	O
or	O
antiglucocorticoid	O
activity	O
.	O
Cortisol	O
,	O
corticosterone	O
,	O
and	O
progesterone	O
competed	O
with	O
dexamethasone	O
for	O
binding	O
,	O
whereas	O
estradiol	O
,	O
dihydrotestosterone	O
,	O
and	O
11-epicortisol	O
competed	O
very	O
little	O
.	O
Binding	O
of	O
dexamethasone	O
to	O
cytosol	O
and	O
nuclear	O
forms	O
of	O
the	O
receptor	B-protein
complex	I-protein
and	O
temperature-sensitive	O
translocation	O
of	O
cytosol	O
forms	O
to	O
nuclear	O
forms	O
were	O
shown	O
.	O
At	O
37	O
degrees	O
C	O
the	O
predominant	O
form	O
of	O
the	O
hormone-receptor	B-protein
complex	I-protein
was	O
nuclear	O
.	O
These	O
results	O
demonstrate	O
that	O
corticosteroids	O
interact	O
with	O
macrophages	O
at	O
physiological	O
concentrations	O
.	O
Nitric	O
oxide	O
signaling	O
:	O
a	O
possible	O
role	O
for	O
G	B-protein
proteins	I-protein
.	O
We	O
have	O
previously	O
reported	O
various	O
inductive	O
effects	O
of	O
nitric	O
oxide	O
on	O
human	O
PBMC	O
.	O
We	O
describe	O
a	O
novel	O
and	O
potentially	O
important	O
mechanism	O
of	O
nitric	O
oxide	O
signaling-through	O
direct	O
activation	O
of	O
guanine	B-protein
nucleotide-binding	I-protein
proteins	I-protein
(	O
G	B-protein
proteins	I-protein
)	O
.	O
We	O
have	O
found	O
that	O
nitric	O
oxide	O
treatment	O
of	O
membranes	O
isolated	O
from	O
fresh	O
human	O
PBMC	O
enhances	O
the	O
ability	O
of	O
these	O
membranes	O
to	O
hydrolyze	O
[	O
gamma-32P	O
]	O
GTP	O
and	O
bind	O
[	O
gamma-35S	O
]	O
GTP	O
.	O
In	O
addition	O
,	O
treatment	O
of	O
whole	O
cells	O
with	O
nitric	O
oxide	O
yielded	O
membranes	O
with	O
enhanced	O
GTPase	O
activity	O
.	O
Furthermore	O
,	O
the	O
GTPase	O
activity	O
of	O
pure	O
,	O
recombinant	O
Gs	B-protein
alpha	I-protein
,	O
Gi	B-protein
alpha	I-protein
1	I-protein
,	O
and	O
p21ras	B-protein
was	O
greatly	O
enhanced	O
by	O
nitric	O
oxide	O
.	O
In	O
support	O
of	O
the	O
existence	O
of	O
this	O
pathway	O
in	O
whole	O
cells	O
,	O
we	O
found	O
that	O
the	O
G	O
protein	O
inhibitor	O
,	O
GDP-beta-S	O
,	O
blocked	O
NF-kappa	B-protein
B	I-protein
translocation	O
induced	O
by	O
nitric	O
oxide	O
or	O
LPS	O
in	O
permeabilized	O
cells	O
.	O
In	O
addition	O
,	O
nitric	O
oxide	O
greatly	O
reduced	O
the	O
pertussis	O
toxin-mediated	O
ADP-ribosylation	O
of	O
45-	B-protein
and	I-protein
41-kDa	I-protein
proteins	I-protein
in	O
membranes	O
of	O
these	O
cells	O
.	O
Because	O
G	B-protein
proteins	I-protein
play	O
a	O
central	O
role	O
in	O
many	O
diverse	O
signaling	O
systems	O
,	O
activation	O
by	O
an	O
endogenous	O
and	O
inducible	O
oxidant	O
may	O
represent	O
a	O
novel	O
signaling	O
pathway	O
.	O
The	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
promoter	O
cis-acting	O
element	O
CLE0	O
mediates	O
induction	O
signals	O
in	O
T	O
cells	O
and	O
is	O
recognized	O
by	O
factors	O
related	O
to	O
AP1	B-protein
and	O
NFAT	B-protein
.	O
Expression	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
gene	O
in	O
T	O
cells	O
is	O
activated	O
by	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
phorbol	O
myristate	O
acetate	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
which	O
mimic	O
antigen	O
stimulation	O
through	O
the	O
T-cell	B-protein
receptor	I-protein
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
fragment	O
containing	O
bp	O
-95	O
to	O
+27	O
of	O
the	O
mouse	O
GM-CSF	O
promoter	O
can	O
confer	O
inducibility	O
to	O
reporter	O
genes	O
in	O
the	O
human	O
Jurkat	O
T-cell	O
line	O
.	O
Here	O
we	O
use	O
an	O
in	O
vitro	O
transcription	O
system	O
to	O
demonstrate	O
that	O
a	O
cis-acting	O
element	O
(	O
positions	O
-54	O
to	O
-40	O
)	O
,	O
referred	O
to	O
as	O
CLE0	O
,	O
is	O
a	O
target	O
for	O
the	O
induction	O
signals	O
.	O
We	O
observed	O
induction	O
with	O
templates	O
containing	O
intact	O
CLE0	O
but	O
not	O
with	O
templates	O
with	O
deleted	O
or	O
mutated	O
CLE0	O
.	O
We	O
also	O
observed	O
that	O
two	O
distinct	O
signals	O
were	O
required	O
for	O
the	O
stimulation	O
through	O
CLE0	O
,	O
since	O
only	O
extracts	O
from	O
cells	O
treated	O
with	O
both	O
phorbol	O
myristate	O
acetate	O
and	O
A23187	O
supported	O
optimal	O
induction	O
.	O
Stimulation	O
probably	O
was	O
mediated	O
by	O
CLE0-binding	B-protein
proteins	I-protein
because	O
depletion	O
of	O
these	O
proteins	O
specifically	O
reduced	O
GM-CSF	B-protein
transcription	O
.	O
One	O
of	O
the	O
binding	B-protein
factors	I-protein
possessed	O
biochemical	O
and	O
immunological	O
features	O
identical	O
to	O
those	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP1	I-protein
.	O
Another	O
factor	O
resembled	O
the	O
T-cell-specific	B-protein
factor	I-protein
NFAT	I-protein
.	O
The	O
characteristics	O
of	O
these	O
two	O
factors	O
are	O
consistent	O
with	O
their	O
involvement	O
in	O
GM-CSF	O
induction	O
.	O
The	O
presence	O
of	O
CLE0-like	O
elements	O
in	O
the	O
promoters	O
of	O
interleukin-3	O
(	O
IL-3	O
)	O
,	O
IL-4	O
,	O
IL-5	O
,	O
GM-CSF	O
,	O
and	O
NFAT	O
sites	O
in	O
the	O
IL-2	O
promoter	O
suggests	O
that	O
the	O
factors	O
we	O
detected	O
,	O
or	O
related	O
factors	O
that	O
recognize	O
these	O
sites	O
,	O
may	O
account	O
for	O
the	O
coordinate	O
induction	O
of	O
these	O
genes	O
during	O
T-cell	O
activation	O
.	O
Identification	O
and	O
characterization	O
of	O
an	O
Alu-containing	O
,	O
T-cell-specific	O
enhancer	O
located	O
in	O
the	O
last	O
intron	O
of	O
the	O
human	O
CD8	O
alpha	O
gene	O
.	O
Expression	O
of	O
the	O
human	O
CD8	O
alpha	O
gene	O
is	O
restricted	O
to	O
cells	O
of	O
the	O
lymphoid	O
lineage	O
and	O
developmentally	O
regulated	O
during	O
thymopoiesis	O
.	O
As	O
an	O
initial	O
step	O
towards	O
understanding	O
the	O
molecular	O
basis	O
for	O
tissue-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
surveyed	O
the	O
surrounding	O
chromatin	O
structure	O
for	O
potential	O
cis-acting	O
regulatory	O
regions	O
by	O
DNase	B-protein
I	I-protein
hypersensitivity	O
mapping	O
and	O
found	O
four	O
hypersensitive	O
sites	O
,	O
three	O
of	O
which	O
were	O
T	O
cell	O
restricted	O
.	O
By	O
using	O
a	O
reporter-based	O
expression	O
approach	O
,	O
a	O
T-cell-specific	O
enhancer	O
was	O
identified	O
by	O
its	O
close	O
association	O
with	O
a	O
prominent	O
T-cell-restricted	O
hypersensitive	O
sites	O
in	O
the	O
last	O
intron	O
of	O
the	O
CD8	O
alpha	O
gene	O
.	O
Deletion	O
studies	O
demonstrated	O
that	O
the	O
minimal	O
enhancer	O
is	O
adjacent	O
to	O
a	O
negative	O
regulatory	O
element	O
.	O
DNA	O
sequence	O
analysis	O
of	O
the	O
minimal	O
enhancer	O
revealed	O
a	O
striking	O
cluster	O
of	O
consensus	O
binding	O
sites	O
for	O
Ets-1	B-protein
,	I-protein
TCF-1	I-protein
,	I-protein
CRE	I-protein
,	I-protein
GATA-3	I-protein
,	I-protein
LyF-1	I-protein
,	I-protein
and	I-protein
bHLH	I-protein
proteins	I-protein
which	O
were	O
verified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
In	O
addition	O
,	O
the	O
5	O
'	O
end	O
of	O
the	O
enhancer	O
was	O
composed	O
of	O
an	O
Alu	O
repeat	O
which	O
contained	O
the	O
GATA-3	O
,	O
bHLH	O
,	O
and	O
LyF-1	O
binding	O
sites	O
.	O
Site-directed	O
mutation	O
of	O
the	O
Ets-1	O
and	O
GATA-3	O
sites	O
dramatically	O
reduced	O
enhancer	O
activity	O
.	O
The	O
functional	O
importance	O
of	O
the	O
other	O
binding	O
sites	O
only	O
became	O
apparent	O
when	O
combinations	O
of	O
mutations	O
were	O
analyzed	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
human	O
CD8	O
alpha	O
gene	O
is	O
regulated	O
by	O
the	O
interaction	O
of	O
multiple	O
T-cell	B-protein
nuclear	I-protein
proteins	I-protein
with	O
a	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
last	O
intron	O
of	O
the	O
gene	O
.	O
Comparison	O
of	O
the	O
CD8	O
alpha	O
enhancer	O
with	O
other	O
recently	O
identified	O
T-cell-specific	O
regulatory	O
elements	O
suggests	O
that	O
a	O
common	O
set	O
of	O
transcription	B-protein
factors	I-protein
regulates	O
several	O
T-cell	O
genes	O
.	O
Molecular	O
regulation	O
of	O
the	O
human	O
IL-3	O
gene	O
:	O
inducible	O
T	O
cell-restricted	O
expression	O
requires	O
intact	O
AP-1	O
and	O
Elf-1	O
nuclear	O
protein	O
binding	O
sites	O
.	O
Interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
is	O
a	O
hematopoietic	B-protein
stem-cell	I-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
that	O
is	O
expressed	O
solely	O
in	O
activated	O
T	O
and	O
NK	O
cells	O
.	O
Studies	O
to	O
date	O
have	O
identified	O
elements	O
5	O
'	O
to	O
the	O
IL-3	O
coding	O
sequences	O
that	O
regulate	O
its	O
transcription	O
,	O
but	O
the	O
sequences	O
that	O
confer	O
T	O
cell-specific	O
expression	O
remain	O
to	O
be	O
clearly	O
defined	O
.	O
We	O
have	O
now	O
identified	O
DNA	O
sequences	O
that	O
are	O
required	O
for	O
T	O
cell-restricted	O
IL-3	O
gene	O
transcription	O
.	O
A	O
series	O
of	O
transient	O
transfections	O
performed	O
with	O
human	O
IL-3-chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
plasmids	O
in	O
T	O
and	O
non-T	O
cells	O
revealed	O
that	O
a	O
plasmid	O
containing	O
319	O
bp	O
of	O
5	O
'	O
flanking	O
sequences	O
was	O
active	O
exclusively	O
in	O
T	O
cells	O
.	O
Deletion	O
analysis	O
revealed	O
that	O
T	O
cell	O
specificity	O
was	O
conferred	O
by	O
a	O
49-bp	O
fragment	O
(	O
bp	O
-319	O
to	O
-270	O
)	O
that	O
included	O
a	O
potential	O
binding	O
site	O
for	O
AP-1	B-protein
transcription	I-protein
factors	I-protein
6	O
bp	O
upstream	O
of	O
a	O
binding	O
site	O
for	O
Elf-1	O
,	O
a	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O
DNaseI	B-protein
footprint	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
analyses	O
performed	O
with	O
MLA-144	O
T	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
this	O
49-bp	O
region	O
contains	O
a	O
nuclear	O
protein	O
binding	O
region	O
that	O
includes	O
consensus	O
AP-1	O
and	O
Elf-1	O
binding	O
sites	O
.	O
In	O
addition	O
,	O
extracts	O
prepared	O
from	O
purified	O
human	O
T	O
cells	O
contained	O
proteins	O
that	O
bound	O
to	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
the	O
AP-1	O
and	O
Elf-1	O
binding	O
sites	O
.	O
In	O
vitro-transcribed	O
and	O
-translated	O
Elf-1	B-protein
protein	I-protein
bound	O
specifically	O
to	O
the	O
Elf-1	O
site	O
,	O
and	O
Elf-1	O
antisera	O
competed	O
and	O
super	O
shifted	O
nuclear	O
protein	O
complexes	O
present	O
in	O
MLA-144	O
nuclear	O
extracts	O
.	O
Moreover	O
,	O
addition	O
of	O
anti-Jun	O
family	O
antiserum	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
reactions	O
completely	O
blocked	O
formation	O
of	O
the	O
AP-1-related	B-protein
complexes	I-protein
.	O
Transient	O
transfection	O
studies	O
in	O
MLA-144	O
T	O
cells	O
revealed	O
that	O
constructs	O
containing	O
mutations	O
in	O
the	O
AP-1	O
site	O
almost	O
completely	O
abolished	O
CAT	O
activity	O
while	O
mutation	O
of	O
the	O
Elf-1	O
site	O
or	O
the	O
NF-IL-3	O
site	O
,	O
a	O
previously	O
described	O
nuclear	O
protein	O
binding	O
site	O
(	O
-155	O
to	O
-148	O
)	O
in	O
the	O
IL-3	O
promoter	O
,	O
reduced	O
CAT	O
activity	O
to	O
<	O
25	O
%	O
of	O
the	O
activity	O
given	O
by	O
wild-type	O
constructs	O
.	O
We	O
conclude	O
that	O
expression	O
of	O
the	O
human	O
IL-3	O
gene	O
requires	O
the	O
AP-1	O
and	O
Elf-1	O
binding	O
sites	O
;	O
however	O
,	O
unlike	O
other	O
previously	O
characterized	O
cytokine	O
genes	O
such	O
as	O
IL-2	B-protein
,	O
the	O
AP-1	B-protein
and	I-protein
Elf-1	I-protein
factors	I-protein
can	O
bind	O
independently	O
in	O
the	O
IL-3	O
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Combination	O
IL-2	B-protein
and	O
IL-4	B-protein
reduces	O
glucocorticoid	O
receptor-binding	O
affinity	O
and	O
T	O
cell	O
response	O
to	O
glucocorticoids	O
.	O
The	O
mechanisms	O
contributing	O
to	O
persistent	O
T	O
cell	O
activation	O
and	O
poor	O
response	O
to	O
glucocorticoids	O
in	O
chronic	O
inflammatory	O
illnesses	O
such	O
as	O
steroid	O
resistant	O
(	O
SR	O
)	O
asthma	O
are	O
poorly	O
defined	O
.	O
We	O
examined	O
the	O
possibility	O
that	O
certain	O
cytokines	O
,	O
specifically	O
IL-2	B-protein
and	O
IL-4	B-protein
,	O
could	O
affect	O
T	O
cell	O
response	O
to	O
glucocorticoids	O
.	O
A	O
[	O
3H	O
]	O
dexamethasone	O
radioligand-binding	O
assay	O
was	O
used	O
to	O
measure	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
and	O
dissociation	O
constant	O
(	O
Kd	O
)	O
in	O
PBMC	O
from	O
normal	O
donors	O
and	O
patients	O
with	O
SR	O
asthma	O
,	O
cultured	O
in	O
the	O
absence	O
and	O
presence	O
of	O
these	O
cytokines	B-protein
.	O
PBMC	O
from	O
normal	O
donors	O
incubated	O
for	O
48	O
h	O
in	O
the	O
presence	O
of	O
combination	O
IL-2	B-protein
+	O
IL-4	B-protein
had	O
nuclear	O
GR	O
with	O
significantly	O
reduced	O
binding	O
affinity	O
(	O
GR	O
Kd	O
=	O
36.1	O
+/-	O
1.63	O
nM	O
,	O
mean	O
+/-	O
SEM	O
;	O
p	O
=	O
0.0001	O
)	O
as	O
compared	O
with	O
PBMC	O
incubated	O
with	O
medium	O
alone	O
(	O
GR	O
Kd	O
=	O
6.74	O
+/-	O
0.46	O
nM	O
)	O
.	O
The	O
cytosolic	O
GR	O
Kd	O
remained	O
unchanged	O
.	O
However	O
,	O
when	O
PBMC	O
were	O
incubated	O
with	O
IL-2	B-protein
alone	O
or	O
IL-4	B-protein
alone	O
,	O
no	O
change	O
in	O
GR-binding	O
affinity	O
was	O
observed	O
.	O
Furthermore	O
,	O
when	O
T	O
cells	O
and	O
non-T	O
cells	O
were	O
individually	O
stimulated	O
with	O
combination	O
IL-2	O
+	O
IL-4	O
,	O
a	O
significant	O
reduction	O
in	O
GR-binding	O
affinity	O
was	O
observed	O
only	O
in	O
the	O
T	O
cell	O
population	O
(	O
p	O
=	O
0.0001	O
)	O
.	O
The	O
IL-2	O
+	O
IL-4-induced	O
alteration	O
in	O
PBMC	O
GR	O
Kd	O
was	O
associated	O
with	O
an	O
increase	O
in	O
GR	O
number	O
(	O
8348	O
+/-	O
964	O
vs	O
1710	O
+/-	O
228	O
sites/cell	O
;	O
p	O
=	O
0.0003	O
)	O
.	O
More	O
importantly	O
,	O
the	O
alteration	O
in	O
PBMC	O
GR-binding	O
affinity	O
with	O
IL-2	B-protein
+	O
IL-4	B-protein
was	O
associated	O
with	O
a	O
functional	O
change	O
in	O
T	O
cell	O
response	O
to	O
methylprednisolone	O
MPN	O
,	O
,	O
a	O
reduced	O
inhibitory	O
effect	O
of	O
MPN	O
on	O
PMA/ionomycin-induced	O
T	O
cell	O
proliferation	O
.	O
These	O
effects	O
of	O
IL-2	B-protein
+	O
IL-4	B-protein
on	O
PBMC	O
GR	B-protein
affinity	O
and	O
response	O
to	O
MPN	O
were	O
blocked	O
by	O
co-incubation	O
with	O
IFN-gamma	B-protein
.	O
Freshly	O
isolated	O
PBMC	O
from	O
four	O
patients	O
with	O
SR	O
asthma	O
had	O
a	O
significantly	O
reduced	O
GR-binding	O
affinity	O
(	O
Kd	O
=	O
40.0	O
+/-	O
2.68	O
nM	O
;	O
p	O
=	O
0.0001	O
)	O
when	O
compared	O
with	O
seven	O
normal	O
subjects	O
(	O
7.15	O
+/-	O
0.41	O
nM	O
)	O
.	O
The	O
altered	O
PBMC	O
GR	O
binding	O
from	O
patients	O
with	O
SR	O
asthma	O
reversed	O
to	O
normal	O
when	O
incubated	O
with	O
medium	O
alone	O
,	O
but	O
was	O
sustained	O
with	O
IL-2	B-protein
+	O
IL-4	B-protein
.	O
These	O
observations	O
suggest	O
that	O
with	O
persistent	O
inflammation	O
certain	O
cytokines	B-protein
may	O
contribute	O
to	O
an	O
impaired	O
response	O
to	O
glucocorticoids	O
.	O
Furthermore	O
,	O
the	O
effects	O
of	O
IL-2	B-protein
and	O
IL-4	B-protein
were	O
blocked	O
by	O
IFN-gamma	B-protein
.	O
Characterization	O
of	O
the	O
human	O
CD4	O
gene	O
promoter	O
:	O
transcription	O
from	O
the	O
CD4	O
gene	O
core	O
promoter	O
is	O
tissue-specific	O
and	O
is	O
activated	O
by	O
Ets	B-protein
proteins	I-protein
.	O
We	O
analyzed	O
the	O
5	O
'	O
transcription	O
control	O
sequences	O
of	O
the	O
human	O
CD4	O
gene	O
.	O
We	O
located	O
the	O
transcription	O
initiation	O
site	O
and	O
showed	O
that	O
the	O
CD4	O
core	O
promoter	O
(	O
positions	O
-40	O
to	O
+16	O
)	O
lacks	O
a	O
classical	O
``	O
TATA	O
''	O
or	O
initiator	O
positioning	O
consensus	O
sequence	O
but	O
directs	O
precise	O
and	O
efficient	O
transcription	O
when	O
coupled	O
to	O
the	O
ubiquitously	O
active	O
simian	O
virus	O
40	O
enhancer	O
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
CD4	O
gene	O
promoter	O
correlated	O
with	O
CD4	O
expression	O
in	O
various	O
cell	O
types	O
.	O
Interestingly	O
,	O
the	O
CD4	O
core	O
promoter	O
also	O
displayed	O
a	O
tissue-specific	O
transcriptional	O
activity	O
.	O
Within	O
this	O
fragment	O
,	O
three	O
nucleic	O
acid	O
sequences	O
are	O
completely	O
conserved	O
in	O
the	O
murine	O
CD4	O
gene	O
.	O
One	O
of	O
these	O
sequences	O
contains	O
a	O
perfect	O
ETS	O
consensus	O
sequence	O
.	O
Another	O
ETS	O
consensus	O
sequence	O
is	O
located	O
1060	O
nt	O
upstream	O
.	O
Electrophoretic-mobility-shift	O
assays	O
showed	O
that	O
the	O
core	O
promoter	O
ETS	O
motif	O
binds	O
an	O
Ets-related	B-protein
protein	I-protein
specifically	O
expressed	O
at	O
high	O
levels	O
in	O
CD4+	O
cells	O
.	O
Moreover	O
,	O
in	O
CD4-	O
cells	O
,	O
overexpression	O
of	O
Ets-1	B-protein
or	O
Ets-2	B-protein
efficiently	O
and	O
specifically	O
activated	O
transcription	O
from	O
the	O
CD4	O
promoter	O
and	O
core	O
promoter	O
.	O
These	O
data	O
indicate	O
that	O
Ets	B-protein
transcription	I-protein
factors	I-protein
play	O
a	O
central	O
role	O
in	O
controlling	O
CD4	O
gene	O
expression	O
,	O
by	O
binding	O
to	O
both	O
a	O
classical	O
remote	O
site	O
and	O
an	O
unusual	O
proximal	O
activator	O
sequence	O
Glucocorticoid	O
receptor	O
activation	O
and	O
inactivation	O
in	O
c	O
ultured	O
human	O
lymphocytes	O
.	O
Although	O
glucocorticoids	O
are	O
not	O
cytolytic	O
for	O
and	O
do	O
not	O
inhibit	O
the	O
growth	O
of	O
the	O
IM-9	O
line	O
of	O
cultured	O
human	O
lymphoblasts	O
,	O
these	O
cells	O
have	O
a	O
high	O
steroid-binding	O
capacity	O
.	O
We	O
have	O
used	O
IM-9	O
cells	O
in	O
order	O
to	O
examine	O
whether	O
unoccupied	B-protein
glucocorticoid	I-protein
receptors	I-protein
are	O
inactivated	O
and	O
activated	O
in	O
intact	O
cells	O
.	O
when	O
IM-9	O
cells	O
are	O
incubated	O
in	O
glucose-free	O
medium	O
in	O
a	O
nitrogen	O
atmosphere	O
,	O
both	O
their	O
ability	O
to	O
bind	O
triamcinolone	O
acetonide	O
and	O
their	O
ATP	O
levels	O
decline	O
and	O
,	O
when	O
glucose	O
and	O
oxygen	O
are	O
reintroduced	O
,	O
ATP	O
levels	O
and	O
receptor	O
activity	O
return	O
.	O
The	O
specific	O
glucocorticoid-binding	O
activity	O
of	O
cytosol	O
prepared	O
from	O
cells	O
exposed	O
to	O
various	O
degrees	O
of	O
energy	O
limitation	O
is	O
directly	O
correlated	O
with	O
the	O
ATP	O
content	O
.	O
Receptor	O
activation	O
in	O
intact	O
cells	O
is	O
rapid	O
and	O
independent	O
of	O
protein	O
synthesis	O
.	O
Cytosol	O
prepared	O
from	O
inactivated	O
cells	O
can	O
not	O
be	O
activated	O
by	O
addition	O
of	O
ATP	O
.	O
The	O
inactivation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
that	O
occurs	O
when	O
cytosol	O
from	O
normal	O
IM-9	O
cells	O
is	O
incubated	O
at	O
25	O
degrees	O
C	O
is	O
inhibited	O
by	O
molybdate	O
,	O
vanadate	O
,	O
fluoride	O
,	O
ATP	O
,	O
and	O
several	O
other	O
nucleotides	O
.	O
The	O
experiments	O
with	O
intact	O
human	O
lymphoblasts	O
suggest	O
that	O
assays	O
of	O
specific	O
glucocorticoid-binding	O
capacity	O
do	O
not	O
necessarily	O
reflect	O
the	O
cellular	O
content	O
of	O
receptor	B-protein
protein	I-protein
.	O
Glucocorticoids	O
and	O
lymphocytes	O
.	O
II	O
.	O
Cell	O
cycle-dependent	O
changes	O
in	O
glucocorticoid	B-protein
receptor	I-protein
content	O
.	O
To	O
study	O
variations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
during	O
the	O
cell	O
cycle	O
,	O
we	O
have	O
separated	O
mitogen-stimulated	O
human	O
peripheral	O
lymphocytes	O
and	O
rat	O
lymph	O
node	O
cells	O
by	O
unit	O
gravity	O
sedimentation	O
and	O
measured	O
glucocorticoid	O
binding	O
in	O
the	O
resultant	O
fractions	O
.	O
By	O
morphologic	O
criteria	O
and	O
thymidine	O
incorporation	O
,	O
the	O
fractions	O
were	O
separated	O
into	O
populations	O
of	O
G0	O
and	O
G1	O
phase	O
and	O
S	O
and	O
post-S	O
phase	O
cells	O
.	O
A	O
2-	O
to	O
3-fold	O
increase	O
in	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
for	O
cells	O
in	O
the	O
S	O
and	O
post-S	O
phase	O
over	O
those	O
in	O
G0	O
and	O
G1	O
,	O
was	O
observed	O
with	O
both	O
nonstimulated	O
rat	O
lymph	O
node	O
cell	O
suspensions	O
and	O
concanavalin	O
A-stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O
These	O
observations	O
together	O
with	O
those	O
from	O
other	O
studies	O
indicate	O
that	O
formation	O
of	O
new	O
glucocorticoid	B-protein
receptors	I-protein
near	O
the	O
S	O
phase	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
proliferating	O
cells	O
.	O
We	O
propose	O
that	O
this	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
during	O
the	O
cell	O
cycle	O
may	O
explain	O
the	O
increase	O
in	O
glucocorticoid	B-protein
receptors	I-protein
in	O
mitogen-stimulated	O
lymphocytes	O
.	O
The	O
leukocyte	O
migration	O
inhibition	O
response	O
to	O
certain	O
breast	B-protein
cancer-related	I-protein
antigens	I-protein
(	O
MCF-7	B-protein
and	O
MuMTV	B-protein
)	O
:	O
their	O
potential	O
as	O
discriminants	O
.	O
Certain	O
oncogenic	O
viruses	O
have	O
been	O
implicated	O
in	O
human	O
breast	O
cancer	O
,	O
including	O
the	O
murine	O
mammary	O
tumor	O
virus	O
(	O
MuMTV	O
)	O
and	O
the	O
Mason-Pfizer	O
monkey	O
virus	O
(	O
MPMV	O
)	O
.	O
We	O
have	O
used	O
the	O
leukocyte	O
migration	O
inhibition	O
(	O
LMI	O
)	O
response	O
to	O
assay	O
the	O
response	O
to	O
several	O
potential	O
breast	O
cancer-related	O
antigens	O
,	O
including	O
MuMTV	B-protein
,	O
MPMV	B-protein
,	O
and	O
a	O
breast	O
cancer	O
cultured	O
cell	O
line	O
,	O
MCF-7	O
,	O
in	O
96	O
breast	O
cancer	O
patients	O
,	O
in	O
32	O
women	O
with	O
benign	O
breast	O
disease	O
,	O
and	O
in	O
67	O
normal	O
women	O
.	O
The	O
lowest	O
tenth	O
percentile	O
of	O
control	O
(	O
LMI	O
)	O
responses	O
was	O
used	O
as	O
the	O
cutoff	O
point	O
to	O
designate	O
responders	O
.	O
Breast	O
cancer	O
patients	O
showed	O
significant	O
responses	O
to	O
MuMTV	B-protein
(	O
49	O
%	O
and	O
to	O
MCF-7	O
(	O
50	O
%	O
)	O
,	O
but	O
not	O
to	O
MPMV	B-protein
(	O
29	O
%	O
)	O
.	O
In	O
a	O
paired-antigen	O
study	O
using	O
MuMTV	B-protein
and	O
MCF-7	B-protein
,	O
75	O
%	O
of	O
the	O
breast	O
cancer	O
patients	O
responded	O
,	O
versus	O
18	O
%	O
of	O
the	O
normal	O
women	O
(	O
P	O
less	O
than	O
0.0050	O
)	O
.	O
The	O
potential	O
for	O
this	O
assay	O
to	O
distinguish	O
``	O
normal	O
''	O
from	O
``	O
breast	O
cancer	O
''	O
was	O
analyzed	O
using	O
a	O
migration	O
index	O
derived	O
from	O
discriminant	O
analysis	O
.	O
The	O
ability	O
of	O
the	O
assay	O
to	O
discriminate	O
``	O
normal	O
''	O
from	O
``	O
cancer	O
''	O
was	O
significant	O
(	O
P	O
less	O
than	O
0.001	O
)	O
and	O
showed	O
a	O
sensitivity	O
of	O
detecting	O
``	O
cancer	O
''	O
of	O
75	O
%	O
.	O
The	O
overall	O
responses	O
to	O
MuMTV	B-protein
and	O
MCF-7	B-protein
were	O
analyzed	O
with	O
reference	O
to	O
certain	O
prognostic	O
factors	O
,	O
but	O
showed	O
no	O
relation	O
to	O
age	O
,	O
menstrual	O
status	O
,	O
estrogen	O
receptor	O
status	O
,	O
or	O
stage	O
of	O
disease	O
.	O
The	O
above	O
reactions	O
suggest	O
that	O
a	O
large	O
proportion	O
of	O
breast	O
cancer	O
patients	O
exhibit	O
presensitization	O
to	O
antigenfs	O
found	O
in	O
MuMTV	B-protein
and	O
MCF-7	B-protein
,	O
which	O
may	O
be	O
cross-reactive	O
with	O
antigens	O
in	O
the	O
primary	O
cancer	O
.	O
These	O
responses	O
appear	O
to	O
be	O
independent	O
of	O
major	O
prognostic	O
variables	O
.	O
Further	O
refinement	O
of	O
this	O
assay	O
may	O
yield	O
one	O
which	O
is	O
more	O
highly	O
discriminating	O
for	O
breast	O
cancer	O
.	O
Chronic	O
lymphatic	O
leukaemia	O
:	O
cellular	O
effects	O
of	O
glucocorticoids	O
in	O
vitro	O
.	O
Glucocorticoid	B-protein
receptor	I-protein
levels	O
and	O
steroid	O
induced	O
inhibition	O
of	O
nucleic	O
acid	O
precursors	O
have	O
been	O
examined	O
in	O
lymphocytes	O
from	O
27	O
patients	O
at	O
different	O
stages	O
of	O
chronic	O
lymphatic	O
leukaemia	O
.	O
No	O
correlation	O
can	O
be	O
found	O
between	O
the	O
level	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
the	O
stage	O
of	O
the	O
disease	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.02	O
)	O
was	O
found	O
between	O
stage	O
O	O
and	O
stage	O
III/IV	O
patients	O
,	O
in	O
terms	O
of	O
the	O
in	O
vitro	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
uridine	O
incorporation	O
.	O
Pyrrolidine	O
dithiocarbamate	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
and	O
TNF	O
production	O
in	O
human	O
monocytes	O
.	O
The	O
human	O
TNF	O
promoter	O
contains	O
four	O
potential	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
-binding	O
sites	O
,	O
with	O
the	O
strongest	O
binding	O
seen	O
for	O
the	O
-605	O
motif	O
.	O
Nuclear	O
extracts	O
from	O
unstimulated	O
cells	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
,	O
Mono	O
Mac	O
6	O
,	O
contain	O
one	O
specific	B-protein
binding	I-protein
protein	I-protein
(	O
complex	B-protein
II	I-protein
)	O
,	O
consistent	O
with	O
a	O
constitutive	B-protein
p50	I-protein
homodimer	I-protein
.	O
Stimulation	O
of	O
Mono	O
Mac	O
6	O
cells	O
with	O
LPS	O
will	O
increase	O
complex	B-protein
II	I-protein
and	O
will	O
strongly	O
induce	O
a	O
second	O
specific	O
complex	O
(	O
complex	B-protein
I	I-protein
)	O
,	O
which	O
represents	O
the	O
p50/65	B-protein
heterodimer	I-protein
.	O
Treatment	O
of	O
Mono	O
Mac	O
6	O
cells	O
with	O
pyrrolidine-dithiocarbamate	O
(	O
PDTC	O
)	O
at	O
300	O
microM	O
will	O
block	O
the	O
LPS-induced	B-protein
complex	I-protein
I	I-protein
almost	O
completely	O
and	O
will	O
reduce	O
complex	B-protein
II	I-protein
to	O
the	O
constitutive	O
level	O
.	O
Binding	O
activity	O
of	O
other	O
nuclear	B-protein
factors	I-protein
that	O
recognize	O
the	O
SP-1	O
and	O
c/EBP	O
motifs	O
of	O
the	O
human	O
TNF	O
promoter	O
is	O
not	O
affected	O
by	O
such	O
treatment	O
.	O
Northern	O
blot	O
analysis	O
demonstrates	O
that	O
PDTC	O
treatment	O
will	O
strongly	O
reduce	O
LPS-induced	B-protein
TNF	I-protein
transcripts	I-protein
.	O
Secreted	O
TNF	B-protein
protein	I-protein
as	O
detected	O
in	O
the	O
Wehi	O
164S/ActD	O
bioassay	O
and	O
in	O
a	O
sandwich	O
immunoassay	O
was	O
similarly	O
reduced	O
by	O
PDTC	O
.	O
Kinetic	O
analyses	O
show	O
that	O
after	O
LPS	O
stimulation	O
,	O
NF-kappa	B-protein
B	I-protein
will	O
peak	O
at	O
1	O
h	O
,	O
TNF	O
transcript	O
prevalence	O
at	O
2	O
h	O
,	O
and	O
TNF	B-protein
protein	I-protein
at	O
4	O
h	O
.	O
PDTC	O
did	O
not	O
shift	O
this	O
response	O
to	O
LPS	O
to	O
a	O
later	O
time	O
,	O
but	O
suppressed	O
NF-kappa	O
B	O
mobilization	O
,	O
TNF	B-protein
transcripts	I-protein
,	O
and	O
TNF	B-protein
protein	I-protein
over	O
the	O
entire	O
8-h	O
observation	O
period	O
.	O
Analysis	O
of	O
freshly	O
isolated	O
,	O
LPS-stimulated	O
blood	O
monocytes	O
showed	O
a	O
similar	O
blockade	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
Furthermore	O
,	O
in	O
these	O
primary	O
cells	O
,	O
induction	O
of	O
TNF	B-protein
transcripts	I-protein
,	O
as	O
determined	O
by	O
Northern	O
blot	O
analysis	O
and	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
was	O
prevented	O
by	O
PDTC	O
as	O
was	O
TNF	B-protein
protein	I-protein
production	O
.	O
These	O
data	O
show	O
that	O
dithiocarbamates	O
can	O
profoundly	O
affect	O
cytokine	O
expression	O
and	O
suggest	O
that	O
NF-kappa	B-protein
B	I-protein
is	O
involved	O
in	O
LPS-induced	O
TNF	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O
Comparing	O
regions	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
which	O
function	O
as	O
transcriptional	O
activating	O
sequences	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
in	O
B	O
cells	O
.	O
The	O
ZEBRA	B-protein
protein	I-protein
activates	O
expression	O
of	O
Epstein-Barr	O
virus	O
early-lytic-cycle	O
genes	O
in	O
human	O
B	O
lymphocytes	O
.	O
Here	O
it	O
is	O
shown	O
that	O
ZEBRA	B-protein
also	O
behaves	O
as	O
a	O
sequence-specific	B-protein
transcriptional	I-protein
activator	I-protein
in	O
Saccharomyces	O
cerevisiae	O
.	O
Deletional	O
mutagenesis	O
defined	O
three	O
regions	O
of	O
ZEBRA	B-protein
that	O
participate	O
in	O
activation	O
in	O
S.	O
cerevisiae	O
.	O
These	O
regions	O
are	O
designated	O
YI	B-protein
(	O
amino	B-protein
acids	I-protein
[	I-protein
aa	I-protein
]	I-protein
1	I-protein
to	I-protein
25	I-protein
)	O
,	O
YII	B-protein
(	O
aa	B-protein
51	I-protein
to	I-protein
102	I-protein
)	O
,	O
and	O
YIII	B-protein
(	O
aa	B-protein
228	I-protein
to	I-protein
245	I-protein
)	O
.	O
Two	O
of	O
the	O
three	O
regions	O
of	O
the	O
native	O
ZEBRA	B-protein
protein	I-protein
act	O
together	O
to	O
mediate	O
activation	O
when	O
assayed	O
on	O
ZEBRA	B-protein
binding	I-protein
sites	I-protein
.	O
However	O
,	O
when	O
fused	O
to	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
GAL	B-protein
4	O
and	O
assayed	O
on	O
GAL4	B-protein
binding	I-protein
sites	I-protein
,	O
regions	B-protein
YII	I-protein
and	I-protein
YIII	I-protein
were	O
each	O
sufficient	O
to	O
confer	O
activation	O
in	O
S.	O
cerevisiae	O
.	O
Regions	O
of	O
ZEBRA	B-protein
which	O
affected	O
activation	O
in	O
S.	O
cerevisiae	O
were	O
also	O
required	O
in	O
human	O
B	O
lymphocytes	O
.	O
The	O
amino-terminal	B-protein
region	I-protein
of	O
ZEBRA	B-protein
(	O
aa	B-protein
1	I-protein
to	I-protein
98	I-protein
)	O
was	O
required	O
for	O
activation	O
both	O
in	O
S.	O
cerevisiae	O
and	O
in	O
human	O
B	O
cells	O
;	O
deletion	O
of	O
the	O
carboxy-terminal	B-protein
18	I-protein
aa	I-protein
also	O
significantly	O
reduced	O
activation	O
in	O
both	O
cell	O
types	O
.	O
Thus	O
,	O
the	O
behavior	O
of	O
ZEBRA	B-protein
in	O
human	O
B	O
cells	O
and	O
S.	O
cerevisiae	O
suggests	O
that	O
the	O
protein	O
contains	O
universal	B-protein
activation	I-protein
motifs	I-protein
that	O
interact	O
with	O
conserved	O
components	O
of	O
the	O
transcription	O
machinery	O
.	O
However	O
,	O
certain	O
deletion	B-protein
mutants	I-protein
of	O
ZEBRA	B-protein
containing	O
mutations	O
in	O
the	O
N-terminal	B-protein
region	I-protein
exhibited	O
discordant	O
behaviors	O
in	O
S.	O
cerevisiae	O
and	O
in	O
B	O
cells	O
.	O
For	O
example	O
,	O
deletion	O
of	O
ZEBRA	B-protein
aa	I-protein
26	I-protein
to	I-protein
51	I-protein
impaired	O
activation	O
to	O
a	O
great	O
extent	O
in	O
B	O
cells	O
but	O
had	O
little	O
or	O
no	O
effect	O
in	O
S.	O
cerevisiae	O
.	O
The	O
discordant	O
mutants	O
may	O
reflect	O
interactions	O
with	O
a	O
variable	B-protein
domain	I-protein
of	O
a	O
conserved	O
component	O
or	O
unique	O
interactions	O
with	O
specialized	O
components	O
of	O
the	O
basal	O
transcription	O
apparatus	O
in	O
different	O
cells	O
.	O
Functional	O
interaction	O
of	O
the	O
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
with	O
the	O
TATA-binding	B-protein
protein	I-protein
and	O
association	O
with	O
transcription	B-protein
factor	I-protein
IIB	I-protein
.	O
Rel	B-protein
family	I-protein
proteins	I-protein
regulate	O
the	O
expression	O
of	O
genes	O
linked	O
to	O
kappa	O
B-binding	O
motifs	O
.	O
Little	O
is	O
known	O
,	O
however	O
,	O
of	O
the	O
mechanism	O
by	O
which	O
they	O
enhance	O
transcription	O
.	O
We	O
have	O
investigated	O
the	O
ability	O
of	O
the	O
v-Rel	B-protein
and	I-protein
c-Rel	I-protein
oncoproteins	I-protein
to	O
interact	O
with	O
components	O
of	O
the	O
basal	O
transcription	O
machinery	O
.	O
Here	O
we	O
report	O
that	O
both	O
the	O
acidic	O
transcription	O
activation	O
domain	O
mapping	O
to	O
the	O
unique	O
C	B-protein
terminus	I-protein
of	O
chicken	B-protein
c-Rel	I-protein
and	O
the	O
F9	B-protein
cell-specific	I-protein
activation	I-protein
region	I-protein
common	O
to	O
both	O
v-Rel	B-protein
and	O
c-Rel	B-protein
interact	O
with	O
the	O
TATA-binding	B-protein
protein	I-protein
(	O
TBP	B-protein
)	O
and	O
transcription	B-protein
factor	I-protein
IIB	I-protein
(	O
TFIIB	B-protein
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
also	O
demonstrate	O
that	O
TPB	B-protein
interaction	O
with	O
Rel	B-protein
activation	I-protein
regions	I-protein
leads	O
to	O
synergistic	O
activation	O
of	O
transcription	O
of	O
a	O
kappa	O
B-linked	O
reporter	O
gene	O
.	O
Combined	O
with	O
the	O
observation	O
that	O
the	O
mouse	B-protein
c-Rel	I-protein
and	I-protein
human	I-protein
RelA	I-protein
proteins	I-protein
also	O
interact	O
with	O
TBP	B-protein
and	O
TFIIB	B-protein
in	O
vitro	O
,	O
these	O
results	O
suggest	O
that	O
association	O
with	O
basal	B-protein
transcription	I-protein
factors	I-protein
is	O
important	O
for	O
the	O
transcriptional	O
activities	O
of	O
Rel	B-protein
family	I-protein
proteins	I-protein
.	O
p21ras	B-protein
and	O
calcineurin	O
synergize	O
to	O
regulate	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
.	O
In	O
T	O
lymphocytes	O
,	O
triggering	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
several	O
signaling	O
cascades	O
which	O
ultimately	O
synergize	O
to	O
induce	O
the	O
activity	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
a	O
DNA	B-protein
binding	I-protein
complex	I-protein
critical	O
to	O
the	O
inducibility	O
and	O
T	O
cell	O
specificity	O
of	O
the	O
T	B-protein
cell	I-protein
growth	I-protein
factor	I-protein
interleukin	B-protein
2	I-protein
.	O
One	O
immediate	O
consequence	O
of	O
T	O
cell	O
activation	O
via	O
the	O
TCR	B-protein
is	O
an	O
increase	O
in	O
cytosolic	O
calcium	O
.	O
Calcium	O
signals	O
are	O
important	O
for	O
NFAT	O
induction	O
,	O
and	O
recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
,	O
a	O
calcium-calmodulin	B-protein
dependent	I-protein
serine-threonine	I-protein
phosphatase	I-protein
,	O
as	O
a	O
prominent	O
component	O
of	O
the	O
calcium	O
signaling	O
pathway	O
in	O
T	O
cells	O
.	O
A	O
second	O
important	O
molecule	O
in	O
TCR	O
signal	O
transduction	O
is	O
the	O
guanine	B-protein
nucleotide	I-protein
binding	I-protein
protein	I-protein
,	O
p21ras	B-protein
,	O
which	O
is	O
coupled	O
to	O
the	O
TCR	B-protein
by	O
a	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
dependent	O
mechanism	O
.	O
The	O
experiments	O
presented	O
here	O
show	O
that	O
expression	O
by	O
transfection	O
of	O
mutationally	O
activated	O
calcineurin	B-protein
or	O
activated	O
p21ras	B-protein
alone	O
is	O
insufficient	O
for	O
NFAT	O
transactivation	O
.	O
However	O
,	O
coexpression	O
of	O
the	O
activated	O
calcineurin	O
with	O
activated	O
p21ras	O
could	O
mimic	O
TCR	O
signals	O
in	O
NFAT	O
induction	O
.	O
These	O
data	O
identify	O
calcineurin	B-protein
and	O
p21ras	B-protein
as	O
cooperative	O
partners	O
in	O
T	O
cell	O
activation	O
.	O
Expression	O
of	O
the	O
chicken	B-protein
GATA	I-protein
factor	I-protein
family	I-protein
during	O
early	O
erythroid	O
development	O
and	O
differentiation	O
.	O
The	O
DNA	O
motif	O
WGATAR	O
has	O
been	O
identified	O
within	O
transcriptional	O
regulatory	O
domains	O
of	O
globin	O
and	O
other	O
erythroid-specific	O
genes	O
and	O
the	O
activator	B-protein
proteins	I-protein
that	O
bind	O
to	O
this	O
regulatory	O
element	O
,	O
the	O
GATA	B-protein
factors	I-protein
,	O
belong	O
to	O
a	O
multi-gene	B-protein
family	I-protein
that	O
is	O
expressed	O
in	O
chicken	O
erythroid	O
cells	O
.	O
Here	O
we	O
show	O
that	O
,	O
as	O
in	O
chickens	O
,	O
multiple	O
members	O
of	O
the	O
GATA	B-protein
factor	I-protein
family	I-protein
are	O
expressed	O
in	O
human	O
and	O
murine	O
erythroid	O
cells	O
.	O
During	O
the	O
early	O
stages	O
of	O
chicken	O
embryogenesis	O
(	O
well	O
before	O
blood	O
island	O
formation	O
)	O
,	O
each	O
of	O
the	O
GATA	B-protein
family	I-protein
members	I-protein
is	O
transcribed	O
with	O
a	O
unique	O
temporal	O
and	O
spatial	O
pattern	O
.	O
In	O
the	O
primitive	O
erythroid	O
lineage	O
,	O
transcription	O
of	O
the	O
embryonic	O
epsilon-globin	O
gene	O
parallels	O
GATA-1	O
expression	O
while	O
the	O
switch	O
to	O
beta-globin	O
transcription	O
in	O
definitive	O
erythroid	O
cells	O
is	O
directly	O
preceded	O
by	O
a	O
pronounced	O
increase	O
in	O
GATA-3	B-protein
accumulation	O
.	O
The	O
timing	O
and	O
pattern	O
of	O
expression	O
of	O
these	O
different	O
mRNAs	O
during	O
avian	O
erythroid	O
development	O
and	O
differentiation	O
suggests	O
that	O
temporally	O
regulated	O
changes	O
in	O
GATA	B-protein
factor	I-protein
expression	O
are	O
required	O
for	O
vertebrate	O
hematopoiesis	O
.	O
Molecular	O
regulation	O
of	O
human	B-protein
interleukin	I-protein
2	I-protein
and	O
T-cell	O
function	O
by	O
interleukin	B-protein
4	I-protein
.	O
Distinct	O
functional	O
T-cell	O
subsets	O
,	O
differing	O
in	O
the	O
patterns	O
of	O
lymphokines	B-protein
produced	O
,	O
regulate	O
cell-mediated	O
and	O
humoral	O
immune	O
responses	O
.	O
The	O
two	O
major	O
types	O
and	O
their	O
principal	O
products	O
,	O
interleukin	B-protein
4	I-protein
and	O
interferon	B-protein
gamma	I-protein
(	O
IL-4	B-protein
and	O
IFN-gamma	B-protein
)	O
,	O
are	O
reciprocally	O
negatively	O
interactive	O
.	O
To	O
analyze	O
the	O
molecular	O
mechanism	O
of	O
IL-4-mediated	O
suppression	O
of	O
cell-mediated	O
immunity	O
we	O
studied	O
its	O
effects	O
on	O
expression	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IFN-gamma	B-protein
.	O
IL-4	B-protein
pretreatment	O
of	O
Jurkat	O
cells	O
prior	O
to	O
stimulation	O
resulted	O
in	O
a	O
decrease	O
in	O
transcription	O
of	O
the	O
IL2	O
gene	O
.	O
IL-4	B-protein
suppressed	O
IL-2	O
and	O
IFN-gamma	O
mRNA	O
levels	O
in	O
primary	O
human	O
T	O
cells	O
,	O
and	O
addition	O
of	O
anti-CD28	B-protein
antibodies	I-protein
relieved	O
this	O
suppression	O
.	O
Using	O
enhancer-reporter	O
constructs	O
,	O
IL-4	B-protein
specifically	O
down-regulated	O
the	O
NFIL-2B	O
element	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
a	O
DNA	O
oligomer	O
containing	O
the	O
NFIL-2B	O
binding	O
site	O
indicated	O
that	O
IL-4	B-protein
inhibited	O
the	O
NFIL-2B	B-protein
complex	I-protein
and	O
that	O
the	O
NFIL-2B	B-protein
DNA	I-protein
binding	I-protein
factor	I-protein
is	O
distinct	O
from	O
AP-	B-protein
1	O
.	O
These	O
results	O
suggest	O
that	O
IL-4	B-protein
may	O
regulate	O
development	O
and	O
function	O
of	O
T-cell	O
subsets	O
involved	O
in	O
cell-mediated	O
immunity	O
in	O
part	O
by	O
inhibiting	B-protein
factors	I-protein
required	O
for	O
transcription	O
of	O
the	O
IL2	O
gene	O
Immunochemical	O
differences	O
between	O
glucocorticoid	B-protein
receptors	I-protein
from	O
corticoid-sensitive	O
and	O
-resistant	O
malignant	O
lymphocytes	O
.	O
We	O
have	O
explored	O
the	O
possibility	O
of	O
using	O
antibodies	B-protein
against	O
purified	O
rat	O
liver	O
glucocorticoid	B-protein
receptors	I-protein
to	O
study	O
the	O
immunochemical	O
properties	O
of	O
glucocorticoid	B-protein
receptors	I-protein
from	O
murine	O
and	O
human	O
malignant	O
lymphocytes	O
.	O
For	O
this	O
purpose	O
,	O
purified	B-protein
immune	I-protein
immunoglobulin	I-protein
G	I-protein
was	O
covalently	O
linked	O
to	O
Sepharose	B-protein
CL-4B	I-protein
.	O
We	O
then	O
examined	O
the	O
ability	O
of	O
the	O
affinity	O
gel	O
to	O
recognize	O
cytosolic	B-protein
[	I-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide-receptor	I-protein
complexes	I-protein
from	O
the	O
corticoid-sensitive	O
(	O
CS	O
)	O
and	O
-resistant	O
strains	O
of	O
mouse	O
lymphoma	O
P1798	O
,	O
from	O
CS	O
lymphocytes	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
,	O
and	O
from	O
a	O
CS	O
clone	O
of	O
human	O
leukemic	O
lymphoblasts	O
in	O
tissue	O
culture	O
(	O
CH6	O
)	O
.	O
Mouse	O
thymus	O
was	O
used	O
as	O
a	O
source	O
of	O
glucocorticoid	B-protein
receptor	I-protein
from	O
normal	O
CS	O
lymphocytes	O
.	O
Whereas	O
the	O
immunoaffinity	O
column	O
retained	O
70	O
to	O
84	O
%	O
of	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
[	B-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide-receptor	I-protein
complexes	I-protein
characteristic	O
of	O
the	O
CS	O
mouse	O
and	O
human	O
lymphocytes	O
,	O
it	O
failed	O
to	O
recognize	O
the	O
27-	O
to	O
28-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-protein
receptor	I-protein
present	O
in	O
corticoid-resistant	O
mouse	O
lymphoma	O
P1798	O
cells	O
.	O
Therefore	O
,	O
under	O
appropriate	O
experimental	O
conditions	O
,	O
it	O
was	O
possible	O
to	O
demonstrate	O
cross-reactivity	O
between	O
the	O
antiserum	O
against	O
rat	B-protein
liver	I-protein
glucocorticoid	I-protein
receptor	I-protein
and	O
the	O
58-	O
to	O
62-A	O
(	O
Stokes	O
radius	O
)	O
glucocorticoid	B-protein
receptor	I-protein
from	O
species	O
as	O
diverse	O
as	O
mouse	O
and	O
humans	O
.	O
Heterogeneity	O
of	O
the	O
in	O
vitro	O
responses	O
to	O
glucocorticoids	O
in	O
acute	O
leukemia	O
.	O
In	O
leukocyte	O
population	O
freshly	O
isolated	O
from	O
the	O
blood	O
of	O
26	O
patients	O
with	O
acute	O
leukemia	O
,	O
we	O
have	O
measured	O
several	O
parameters	O
including	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
,	O
and	O
steroid-induced	O
cell	O
lysis	O
.	O
In	O
addition	O
,	O
in	O
some	O
cases	O
,	O
the	O
short-term	O
response	O
to	O
steroid	O
therapy	O
was	O
determined	O
.	O
Although	O
,	O
in	O
all	O
the	O
patients	O
studied	O
,	O
leukocytes	O
were	O
found	O
to	O
contain	O
glucocorticoid	B-protein
receptors	I-protein
,	O
we	O
failed	O
to	O
demonstrate	O
any	O
correlation	O
between	O
the	O
level	O
of	O
binding	O
sites	O
and	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
response	O
to	O
glucocorticoids	O
.	O
This	O
absence	O
of	O
correlation	O
could	O
be	O
in	O
part	O
explained	O
by	O
the	O
marked	O
heterogeneity	O
of	O
the	O
steroid	O
response	O
demonstrated	O
in	O
leukocyte	O
subpopulations	O
.	O
It	O
appears	O
,	O
however	O
,	O
that	O
the	O
degree	O
of	O
steroid	O
action	O
in	O
vitro	O
as	O
well	O
as	O
the	O
extent	O
of	O
spontaneous	O
and	O
dexamethasone-induced	O
cell	O
death	O
may	O
be	O
related	O
to	O
the	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Glucocorticoid	B-protein
receptors	I-protein
in	O
cytosol	O
and	O
nuclear	O
extract	O
of	O
human	O
leukocytes	O
.	O
Cortisol	O
binding	O
by	O
cytosol	O
and	O
0.4	O
M	O
KCl	O
extract	O
of	O
the	O
nuclear	O
fraction	O
of	O
human	O
leukocytes	O
were	O
studied	O
by	O
gel	O
chromatography	O
and	O
ion	O
exchange	O
filtration	O
on	O
DEAE	O
cellulose	O
.	O
The	O
cytoplasmic	B-protein
cortisol	I-protein
binding	I-protein
protein	I-protein
has	O
a	O
molecular	O
weight	O
95	O
000	O
and	O
the	O
soluble	B-protein
nuclear	I-protein
binding	I-protein
protein	I-protein
50	O
000	O
.	O
The	O
absence	O
of	O
the	O
uptake	O
of	O
radioactive	O
cortisol	O
by	O
isolated	O
nuclei	O
and	O
the	O
apparent	O
requirement	O
of	O
the	O
cytosol	O
for	O
glucocorticoid	O
specific	O
binding	O
in	O
nuclear	O
receptor	O
sites	O
was	O
observed	O
.	O
The	O
association	O
constant	O
characterising	O
the	O
binding	O
of	O
cortisol	O
to	O
cytosol	O
was	O
KA	O
=	O
3.5	O
.	O
10	O
(	O
9	O
)	O
l/mol	O
.	O
Corticosteroid-induced	O
lymphopenia	O
,	O
immunosuppression	O
,	O
and	O
body	O
defense	O
.	O
The	O
apparent	O
paradox	O
of	O
heightened	O
adrenal	O
corticosteroid	O
levels	O
associated	O
with	O
reduction	O
in	O
the	O
competence	O
of	O
the	O
body	O
's	O
defensive	O
apparatus	O
to	O
cope	O
with	O
exposure	O
to	O
new	O
microbial	B-protein
antigens	I-protein
is	O
considered	O
.	O
The	O
question	O
is	O
asked	O
how	O
this	O
lowered	O
defensive	O
capability	O
,	O
which	O
occurs	O
in	O
the	O
face	O
of	O
a	O
threat	O
to	O
body	O
integrity	O
,	O
is	O
consistent	O
with	O
Cannon	O
's	O
principals	O
of	O
the	O
``	O
wisdom	O
of	O
the	O
''	O
The	O
suggestion	O
is	O
offered	O
that	O
the	O
immunologic	O
response	O
to	O
self-antigens	B-protein
exposed	O
by	O
disease	O
or	O
trauma	O
may	O
be	O
suppressed	O
by	O
corticosteroid	O
to	O
offset	O
the	O
likelihood	O
of	O
autoimmune	O
attack	O
.	O
Protein	B-protein
tyrosine	I-protein
kinase	I-protein
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
cytokines	B-protein
in	O
human	O
blood	O
monocytes	O
.	O
Bacterial	O
LPS	O
induce	O
production	O
of	O
cytokines	B-protein
such	O
as	O
IL-1	B-protein
,	O
IL-6	B-protein
,	O
and	O
TNF	B-protein
in	O
mononuclear	O
phagocytes	O
,	O
and	O
this	O
represents	O
a	O
central	O
component	O
in	O
the	O
pathogenesis	O
of	O
septic	O
shock	O
syndrome	O
.	O
However	O
,	O
the	O
mechanisms	O
by	O
which	O
LPS	O
activates	O
these	O
cells	O
to	O
express	O
cytokines	B-protein
are	O
not	O
completely	O
characterized	O
.	O
The	O
present	O
study	O
addressed	O
the	O
role	O
of	O
different	O
protein	B-protein
kinases	I-protein
in	O
the	O
LPS	O
induction	O
of	O
cytokines	B-protein
.	O
It	O
is	O
shown	O
that	O
LPS	O
induced	O
a	O
12-	O
to	O
16-fold	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
and	O
TNF-alpha	O
mRNA	O
levels	O
,	O
and	O
this	O
was	O
completely	O
or	O
more	O
than	O
80	O
%	O
blocked	O
by	O
the	O
protein	O
tyrosine	O
kinase	O
specific	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
at	O
the	O
concentrations	O
of	O
1.7	O
and	O
37	O
microM	O
,	O
respectively	O
.	O
Protein	B-protein
kinase	I-protein
C	I-protein
inhibition	O
by	O
staurosporine	O
reduced	O
LPS	O
induction	O
of	O
TNF-alpha	B-protein
,	O
whereas	O
it	O
had	O
no	O
effects	O
on	O
IL-6	B-protein
and	O
IL-1	O
beta	O
.	O
Inhibition	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
by	O
H89	O
reduced	O
IL-6	O
mRNA	O
levels	O
but	O
did	O
not	O
detectably	O
change	O
IL-1	O
beta	O
or	O
TNF-alpha	O
mRNA	O
levels	O
.	O
In	O
contrast	O
,	O
LPS	O
did	O
not	O
increase	O
leukemia	O
inhibitory	O
factor	O
mRNA	O
,	O
which	O
was	O
constitutively	O
expressed	O
and	O
not	O
significantly	O
reduced	O
by	O
these	O
inhibitors	O
.	O
In	O
addition	O
to	O
cytokine	O
mRNA	O
levels	O
,	O
LPS-induced	O
IL-6	O
protein	O
synthesis	O
and	O
IL-6	O
bioactivity	O
were	O
also	O
reduced	O
to	O
baseline	O
levels	O
by	O
the	O
PTK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
.	O
Both	O
PTK	O
inhibitors	O
also	O
reduced	O
the	O
LPS	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
which	O
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
cytokine	O
genes	O
such	O
as	O
IL-6	O
and	O
TNF-alpha	O
.	O
The	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
also	O
reduced	O
by	O
H89	O
,	O
whereas	O
staurosporine	O
had	O
no	O
effect	O
on	O
this	O
response	O
.	O
In	O
summary	O
,	O
these	O
findings	O
suggest	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
and	O
protein	B-protein
kinase	I-protein
A	I-protein
appear	O
to	O
have	O
selective	O
effects	O
in	O
the	O
LPS	O
induction	O
of	O
cytokines	B-protein
,	O
whereas	O
PTK	B-protein
is	O
required	O
for	O
LPS	O
induction	O
of	O
a	O
broad	O
spectrum	O
of	O
cytokines	B-protein
and	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
monocytes	O
.	O
In	O
vivo	O
control	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
The	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
stored	O
in	O
the	O
cytoplasm	O
in	O
complexes	O
with	O
the	O
inhibitor	B-protein
protein	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
It	O
has	O
been	O
shown	O
in	O
vitro	O
that	O
dissociation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
these	O
complexes	O
results	O
in	O
active	B-protein
NF-kappa	I-protein
B	I-protein
.	O
In	O
this	O
report	O
we	O
show	O
that	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
activation	O
of	O
B	O
or	O
pre-B	O
cells	O
results	O
in	O
loss	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
in	O
vivo	O
.	O
Many	O
liberated	O
NF-kappa	B-protein
B	I-protein
dimers	I-protein
reached	O
the	O
nucleus	O
,	O
where	O
increased	O
c-rel	B-protein
,	O
p65	O
and	O
p50	O
were	O
detected	O
by	O
immunoblotting	O
and	O
by	O
DNA	O
binding	O
assays	O
.	O
Some	O
liberated	B-protein
dimers	I-protein
were	O
retained	O
in	O
the	O
cytoplasm	O
,	O
however	O
,	O
through	O
binding	O
to	O
newly	O
synthesized	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
a	O
finding	O
which	O
strongly	O
suggests	O
(	O
i	O
)	O
that	O
the	O
LPS-induced	O
signal	O
causes	O
dissociation	O
of	O
complexes	O
rather	O
than	O
preventing	O
their	O
association	O
and	O
(	O
ii	O
)	O
that	O
dissociation	O
results	O
from	O
modification	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
not	O
of	O
c-rel	B-protein
or	O
p65	B-protein
.	O
No	O
effect	O
of	O
LPS	O
treatment	O
was	O
detected	O
on	O
p105	B-protein
or	O
p100	B-protein
,	O
which	O
also	O
retain	O
rel	B-protein
family	I-protein
members	I-protein
in	O
the	O
cytoplasm	O
.	O
Quite	O
unexpectedly	O
,	O
we	O
also	O
found	O
that	O
in	O
unstimulated	O
cells	O
there	O
is	O
a	O
constant	O
ongoing	O
process	O
of	O
degradation	O
and	O
replacement	O
of	O
complexed	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O
We	O
propose	O
that	O
this	O
turnover	O
results	O
in	O
the	O
low	O
level	O
of	O
active	B-protein
NF-kappa	I-protein
B	I-protein
presumably	O
necessary	O
even	O
in	O
the	O
unstimulated	O
cell	O
,	O
and	O
that	O
the	O
high	O
rate	O
of	O
synthesis	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
provides	O
the	O
ability	O
to	O
turn	O
off	O
NF-kappa	B-protein
B	I-protein
activity	O
rapidly	O
as	O
soon	O
as	O
the	O
activating	O
signal	O
ceases	O
.	O
Identification	O
of	O
a	O
killer	O
cell-specific	O
regulatory	O
element	O
of	O
the	O
mouse	O
perforin	O
gene	O
:	O
an	O
Ets-binding	O
site-homologous	O
motif	O
that	O
interacts	O
with	O
Ets-related	B-protein
proteins	I-protein
.	O
The	O
gene	O
encoding	O
the	O
cytolytic	B-protein
protein	I-protein
perforin	B-protein
is	O
selectively	O
expressed	O
by	O
activated	O
killer	O
lymphocytes	O
.	O
To	O
understand	O
the	O
mechanisms	O
underlying	O
the	O
cell-type-specific	O
expression	O
of	O
this	O
gene	O
,	O
we	O
have	O
characterized	O
the	O
regulatory	O
functions	O
and	O
the	O
DNA-protein	O
interactions	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
mouse	O
perforin	O
gene	O
(	O
Pfp	O
)	O
.	O
A	O
region	O
extending	O
from	O
residues	O
+62	O
through	O
-141	O
,	O
which	O
possesses	O
the	O
essential	O
promoter	O
activity	O
,	O
and	O
regions	O
further	O
upstream	O
,	O
which	O
are	O
able	O
to	O
either	O
enhance	O
or	O
suppress	O
gene	O
expression	O
,	O
were	O
identified	O
.	O
The	O
region	O
between	O
residues	O
-411	O
and	O
-566	O
was	O
chosen	O
for	O
further	O
characterization	O
,	O
since	O
it	O
contains	O
an	O
enhancer-like	O
activity	O
.	O
We	O
have	O
identified	O
a	O
32-mer	O
sequence	O
(	O
residues	O
-491	O
to	O
-522	O
)	O
which	O
appeared	O
to	O
be	O
capable	O
of	O
enhancing	O
gene	O
expression	O
in	O
a	O
killer	O
cell-specific	O
manner	O
.	O
Within	O
this	O
segment	O
,	O
a	O
9-mer	O
motif	O
(	O
5'-ACAGGAAGT-3	O
'	O
,	O
residues	O
-505	O
to	O
-497	O
;	O
designated	O
NF-P	O
motif	O
)	O
,	O
which	O
is	O
highly	O
homologous	O
to	O
the	O
Ets	O
proto-oncoprotein-binding	O
site	O
,	O
was	O
found	O
to	O
interact	O
with	O
two	O
proteins	O
,	O
NF-P1	B-protein
and	O
NF-P2	B-protein
.	O
NF-P2	B-protein
appears	O
to	O
be	O
induced	O
by	O
reagents	O
known	O
to	O
up-regulate	O
the	O
perforin	O
message	O
level	O
and	O
is	O
present	O
exclusively	O
in	O
killer	O
cells	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
and	O
UV	O
cross-linking	O
experiments	O
revealed	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
may	O
possess	O
common	O
DNA-binding	B-protein
subunits	I-protein
.	O
However	O
,	O
the	O
larger	O
native	O
molecular	O
mass	O
of	O
NF-P1	B-protein
suggests	O
that	O
NF-P1	B-protein
contains	O
an	O
additional	O
non-DNA-binding	B-protein
subunit	I-protein
(	O
s	O
)	O
.	O
In	O
view	O
of	O
the	O
homology	O
between	O
the	O
NF-P	B-protein
motif	I-protein
and	O
other	O
Ets	B-protein
proto-oncoprotein-binding	I-protein
sites	I-protein
,	O
it	O
is	O
postulated	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
belong	O
to	O
the	O
Ets	B-protein
protein	I-protein
family	I-protein
.	O
Results	O
obtained	O
from	O
the	O
binding	O
competition	O
assay	O
,	O
nevertheless	O
,	O
suggest	O
that	O
NF-P1	B-protein
and	O
NF-P2	B-protein
are	O
related	O
to	O
but	O
distinct	O
from	O
Ets	B-protein
proteins	I-protein
,	O
,	O
Ets-1	B-protein
,	O
Ets-2	B-protein
,	O
and	O
NF-AT/Elf-1	B-protein
,	O
known	O
to	O
be	O
expressed	O
in	O
T	O
cells	O
.	O
The	O
role	O
of	O
NF-kappa	O
B1	O
(	O
p50/p105	O
)	O
gene	O
expression	O
in	O
activation	O
of	O
human	O
blood	O
T-lymphocytes	O
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
.	O
Stimulation	O
of	O
primary	O
human	O
T-lymphocytes	O
via	O
CD2	B-protein
and	I-protein
CD28	I-protein
adhesion	I-protein
molecules	I-protein
induces	O
a	O
long-lasting	O
proliferation	O
(	O
>	O
3	O
weeks	O
)	O
.	O
This	O
potent	O
activation	O
does	O
not	O
require	O
accessory	O
cells	O
,	O
such	O
as	O
monocytes	O
,	O
but	O
depends	O
on	O
persistent	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
secretion	O
and	O
receptivity	O
,	O
which	O
is	O
associated	O
with	O
high	O
and	O
prolonged	O
expression	O
of	O
the	O
inducible	O
CD25/IL-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
chain	O
gene	O
.	O
The	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
participates	O
in	O
the	O
regulation	O
of	O
both	O
IL-2	O
and	O
IL-2R	O
alpha	O
genes	O
,	O
as	O
well	O
as	O
multiple	O
cellular	O
genes	O
involved	O
in	O
T-cell	O
proliferation	O
.	O
To	O
evaluate	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	O
peripheral	O
blood	O
T-lymphocytes	O
,	O
we	O
previously	O
analyzed	O
the	O
activation	O
of	O
NF-kappa	B-protein
B-related	I-protein
complexes	I-protein
in	O
response	O
to	O
CD2+CD28	O
costimulation	O
.	O
We	O
demonstrated	O
a	O
long-term	O
induction	O
of	O
p50/p65	B-protein
heterodimer	I-protein
,	O
a	O
putative	B-protein
p65/c-Rel	I-protein
heterodimer	I-protein
,	O
and	O
a	O
constitutive	O
nuclear	O
expression	O
of	O
KBF1/p50	B-protein
homodimers	I-protein
.	I-protein
As	O
the	O
role	O
of	O
p50	B-protein
remains	O
unclear	O
,	O
we	O
focused	O
our	O
present	O
study	O
on	O
NF-kappa	B-protein
B1	I-protein
(	O
p50/p105	B-protein
)	O
gene	O
regulation	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Western	O
and	O
Northern	O
blot	O
analyses	O
,	O
we	O
studied	O
NF-kappa	O
B1	O
gene	O
expression	O
during	O
T-cell	O
stimulation	O
via	O
CD2+CD28	B-protein
.	O
We	O
observed	O
a	O
transient	O
4-	O
to	O
5-fold	O
increase	O
of	O
NF-kappa	O
B1	O
gene	O
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
,	O
lasting	O
for	O
at	O
least	O
24	O
h	O
.	O
p50	O
DNA-binding	O
activity	O
apparently	O
stays	O
highly	O
controlled	O
when	O
p105	O
expression	O
is	O
enhanced	O
by	O
a	O
physiological	O
stimulus	O
of	O
peripheral	O
blood	O
T-cells	O
.	O
Partial	O
inhibition	O
of	O
p50	O
and	O
p105	O
expression	O
by	O
NF-kappa	B-protein
B1	I-protein
antisense	O
oligonucleotides	O
significantly	O
reduced	O
T-cell	O
proliferation	O
and	O
CD25/IL-2R	B-protein
alpha	I-protein
cell	O
surface	O
expression	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Vitamin	B-protein
D	I-protein
receptor	I-protein
quantitation	O
in	O
human	O
blood	O
mononuclear	O
cells	O
in	O
health	O
and	O
disease	O
.	O
Vitamin	B-protein
D	I-protein
receptor	I-protein
(	O
VDR	O
)	O
concentration	O
was	O
quantitated	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
patients	O
with	O
absorptive	O
hypercalciuria	O
(	O
AH	O
)	O
and	O
patients	O
with	O
high	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
due	O
to	O
acquired	O
or	O
transient	O
disease	O
states	O
and	O
the	O
results	O
compared	O
to	O
those	O
in	O
normal	O
subjects	O
.	O
VDR	O
concentration	O
in	O
resting	O
cells	O
was	O
not	O
different	O
between	O
the	O
three	O
groups	O
and	O
represented	O
constitutive	O
receptor	O
expression	O
of	O
monocytes	O
.	O
Following	O
activation	O
with	O
phytohemagglutinin	B-protein
,	O
patients	O
with	O
hypercalcitriolemia	O
demonstrated	O
significantly	O
greater	O
VDR	O
concentrations	O
.	O
Patients	O
with	O
AH	O
demonstrated	O
a	O
normal	O
value	O
for	O
the	O
group	O
,	O
but	O
6	O
patients	O
had	O
significantly	O
greater	O
concentrations	O
of	O
VDR	B-protein
despite	O
normal	O
plasma	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
four	O
of	O
the	O
patients	O
.	O
Proliferation	O
,	O
as	O
assessed	O
from	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
inversely	O
correlated	O
with	O
serum	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
was	O
significant	O
(	O
R	O
=	O
-0.299	O
,	O
p	O
=	O
0.048	O
)	O
.	O
Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
PBMC	O
provide	O
a	O
useful	O
system	O
for	O
studying	O
VDR	B-protein
status	O
in	O
transient	O
or	O
acquired	O
states	O
of	O
hypercalcitriolemia	O
.	O
Furthermore	O
,	O
the	O
studies	O
in	O
patients	O
with	O
absorptive	O
hypercalciuria	O
disclosed	O
it	O
to	O
be	O
a	O
heterogeneous	O
disorder	O
,	O
characterized	O
by	O
both	O
vitamin	O
D-dependent	O
and	O
D-independent	O
forms	O
of	O
receptor	O
up-regulation	O
.	O
Reactive	O
oxygen	O
intermediates	O
activate	O
NF-kappa	B-protein
B	I-protein
in	O
a	O
tyrosine	O
kinase-dependent	O
mechanism	O
and	O
in	O
combination	O
with	O
vanadate	O
activate	O
the	O
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
in	O
human	O
lymphocytes	O
.	O
We	O
have	O
previously	O
observed	O
that	O
ionizing	O
radiation	O
induces	O
tyrosine	O
phosphorylation	O
in	O
human	O
B-lymphocyte	O
precursors	O
by	O
stimulation	O
of	O
unidentified	O
tyrosine	B-protein
kinases	I-protein
and	O
this	O
phosphorylation	O
is	O
substantially	O
augmented	O
by	O
vanadate	O
.	O
Ionizing	O
radiation	O
generates	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
.	O
Because	O
H2O2	O
is	O
a	O
potent	O
ROI	O
generator	O
that	O
readily	O
crosses	O
the	O
plasma	O
membrane	O
,	O
we	O
used	O
H2O2	O
to	O
examine	O
the	O
effects	O
of	O
ROI	O
on	O
signal	O
transduction	O
.	O
We	O
now	O
provide	O
evidence	O
that	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
and	O
the	O
free	O
radical	O
scavenger	O
N-acetyl-cysteine	O
inhibit	O
both	O
radiation-induced	O
and	O
H2O2-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
indicating	O
that	O
activation	O
triggered	O
by	O
ROI	O
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activity	O
.	O
H2O2	O
was	O
found	O
to	O
stimulate	O
Ins-1	B-protein
,	I-protein
4	I-protein
,	I-protein
5-P3	I-protein
production	O
in	O
a	O
tyrosine	O
kinase-dependent	O
manner	O
and	O
to	O
induce	O
calcium	O
signals	O
that	O
were	O
greatly	O
augmented	O
by	O
vanadate	O
.	O
The	O
synergistic	O
induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
H2O2	O
plus	O
vanadate	O
included	O
physiologically	O
relevant	O
proteins	O
such	O
as	O
PLC	B-protein
gamma	I-protein
1	I-protein
.	O
Although	O
treatment	O
of	O
cells	O
with	O
H2O2	O
alone	O
did	O
not	O
affect	O
the	O
activity	O
of	O
src	B-protein
family	I-protein
kinases	I-protein
,	O
treatment	O
with	O
H2O2	O
plus	O
vanadate	O
led	O
to	O
activation	O
of	O
the	O
p56lck	B-protein
and	I-protein
p59fyn	I-protein
tyrosine	I-protein
kinases	I-protein
.	O
The	O
combined	O
inhibition	O
of	O
phosphatases	B-protein
and	O
activation	O
of	O
kinases	B-protein
provides	O
a	O
potent	O
mechanism	O
for	O
the	O
synergistic	O
effects	O
of	O
H2O2	O
plus	O
vanadate	O
.	O
Induction	O
of	O
tyrosine	O
phosphorylation	O
by	O
ROI	O
may	O
thus	O
lead	O
to	O
many	O
of	O
the	O
pleiotropic	O
effects	O
of	O
ROI	O
in	O
lymphoid	O
cells	O
,	O
including	O
downstream	O
activation	O
of	O
PLC	B-protein
gamma	I-protein
1	I-protein
and	O
NF-kappa	B-protein
B	I-protein
Influence	O
of	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
and	O
serum	B-protein
albumin	I-protein
on	O
the	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
by	O
human	O
erythrocytes	O
.	O
The	O
influence	O
of	O
human	B-protein
serum	I-protein
albumin	I-protein
and	O
sex	B-protein
hormone	I-protein
binding	I-protein
globulin	I-protein
(	O
SHBG	B-protein
)	O
on	O
the	O
enzymic	O
conversion	O
of	O
androstenedione	O
to	O
testosterone	O
in	O
human	O
erythrocytes	O
was	O
investigated	O
in	O
vitro	O
.	O
Total	O
plasma	O
and	O
albumin	B-protein
delayed	O
the	O
conversion	O
rate	O
of	O
androstenedione	O
,	O
while	O
SHBG	B-protein
increased	O
it	O
markedly	O
.	O
The	O
effect	O
of	O
SHBG	B-protein
was	O
largely	O
abolished	O
by	O
heating	O
to	O
60	O
degrees	O
C	O
for	O
1	O
h	O
and	O
by	O
saturating	O
its	O
binding	O
sites	O
by	O
DHT	O
.	O
The	O
effect	O
of	O
both	O
proteins	O
was	O
found	O
to	O
be	O
related	O
to	O
their	O
concentration	O
.	O
It	O
appears	O
that	O
the	O
binding	O
sites	O
of	O
albumin	B-protein
provide	O
a	O
mechanism	O
for	O
retarding	O
androstenedione	O
uptake	O
by	O
the	O
erythrocytes	O
and	O
that	O
the	O
high	O
binding	O
affinity	O
of	O
SHBG	B-protein
for	O
testosterone	O
facilitates	O
the	O
diffusion	O
of	O
this	O
steroid	O
out	O
of	O
the	O
cell	O
and	O
thus	O
,	O
displaces	O
the	O
chemical	O
equilibrium	O
within	O
the	O
cell	O
.	O
Glucocorticoids	O
and	O
lymphocytes	O
.	O
I	O
.	O
Increased	O
glucocorticoid	B-protein
receptor	I-protein
levels	O
in	O
antigen-stimulated	O
lymphocytes	O
.	O
Recently	O
a	O
2-	O
to	O
3-fold	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
human	O
peripheral	O
lymphocytes	O
has	O
been	O
noted	O
after	O
in	O
vitro	O
mitogen	O
stimulation	O
.	O
Here	O
,	O
we	O
extend	O
these	O
observations	O
to	O
in	O
vivo	O
immunization	O
.	O
After	O
unilateral	O
immunization	O
of	O
adrenalectomized	O
male	O
rats	O
,	O
a	O
50	O
%	O
increase	O
in	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
determined	O
by	O
binding	O
of	O
dexamethasone	O
,	O
was	O
observed	O
in	O
cell	O
suspensions	O
of	O
homolateral	O
lymph	O
nodes	O
over	O
those	O
from	O
the	O
contralateral	O
nonimmunized	O
side	O
of	O
the	O
same	O
animal	O
.	O
The	O
association	O
constant	O
for	O
dexamethasone	O
was	O
similar	O
in	O
both	O
groups	O
,	O
as	O
was	O
the	O
stereospecificity	O
for	O
various	O
steroids	O
,	O
the	O
time	O
course	O
of	O
cytoplasmic	O
and	O
nuclear	O
association	O
,	O
and	O
cytoplasmic-to-nuclear	O
translocation	O
.	O
Despite	O
a	O
50	O
%	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	O
receptor	O
sites	O
per	O
cell	O
,	O
the	O
cells	O
from	O
the	O
homolateral	O
and	O
controlateral	O
lymph	O
nodes	O
were	O
equally	O
sensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
dexamethasone	O
,	O
as	O
determined	O
by	O
measurements	O
of	O
the	O
incorporation	O
of	O
radiolabeled	O
precursors	O
of	O
protein	O
,	O
RNA	O
,	O
and	O
DNA	O
,	O
or	O
measurements	O
of	O
in	O
vitro	O
cell	O
survival	O
.	O
Glucocorticoid	O
receptors	O
and	O
actions	O
in	O
rat	O
thymocytes	O
and	O
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O
After	O
reviewing	O
briefly	O
our	O
earlier	O
studies	O
on	O
glucocorticoid	O
receptors	O
and	O
mechanisms	O
in	O
thymus	O
cells	O
,	O
we	O
have	O
outlined	O
results	O
from	O
the	O
following	O
two	O
areas	O
of	O
current	O
interest	O
in	O
our	O
laboratories	O
:	O
the	O
``	O
life-cycle	O
''	O
of	O
glucocorticoid	O
receptors	O
and	O
complexes	O
in	O
thymus	O
cells	O
,	O
and	O
the	O
levels	O
of	O
glucocorticoid	O
receptors	O
and	O
sensitivity	O
in	O
immunologically	O
stimulated	O
human	O
peripheral	O
lymphocytes	O
.	O
Several	O
of	O
our	O
results	O
on	O
energetics	O
and	O
kinetics	O
of	O
hormone	O
binding	O
to	O
glucocorticoid	B-protein
receptors	I-protein
in	O
rat	O
thymus	O
cells	O
seem	O
to	O
require	O
extension	O
of	O
the	O
simplest	O
model	O
of	O
hormone-receptor	O
transformations	O
in	O
intact	O
cells	O
.	O
ATP-depletion	O
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
nonbinding	O
form	O
of	O
the	O
receptor	O
;	O
``	O
chase	O
''	O
experiments	O
suggest	O
reaction	O
of	O
hormone	O
directly	O
with	O
nuclear-bound	O
receptor	O
;	O
experiments	O
on	O
depletion	O
and	O
replenishment	O
of	O
cytoplasmic	B-protein
receptor	I-protein
using	O
cortisol	O
and	O
dexamethasone	O
suggest	O
the	O
existence	O
of	O
at	O
least	O
two	O
subpopulations	O
of	O
nuclear-bound	B-protein
hormone-receptor	I-protein
complex	I-protein
.	O
We	O
have	O
found	O
that	O
mitogen	O
or	O
immunologic	O
stimulation	O
of	O
human	O
peripheral	O
lymphocytes	O
in	O
culture	O
leads	O
within	O
24	O
h	O
or	O
so	O
to	O
a	O
striking	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptor	I-protein
sites	O
per	O
cell	O
.	O
We	O
believe	O
this	O
increase	O
may	O
be	O
due	O
to	O
partial	O
synchronization	O
of	O
the	O
cell	O
population	O
in	O
a	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
which	O
receptor	O
content	O
is	O
high	O
.	O
Contrary	O
to	O
the	O
widely	O
held	O
view	O
that	O
mitogen-stimulated	O
cells	O
become	O
insensitive	O
to	O
glucocorticoids	O
,	O
our	O
experiments	O
show	O
that	O
with	O
respect	O
to	O
inhibition	O
of	O
thymidine	O
and	O
uridine	O
incorporation	O
and	O
glucose	O
uptake	O
,	O
the	O
cells	O
are	O
highly	O
sensitive	O
to	O
dexamethasone	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
after	O
stimulation	O
with	O
concanavalin	B-protein
A	I-protein
.	O
Nuclear	O
glucocorticoid	O
binding	O
in	O
chronic	O
lymphatic	O
leukemia	O
lymphocytes	O
.	O
A	O
reliable	O
procedure	O
is	O
described	O
for	O
isolating	O
3H-triamcinolone	B-protein
acetonide	I-protein
(	I-protein
3H-TA	I-protein
)	I-protein
receptor	I-protein
complexes	I-protein
from	O
purified	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
lymphocyte	O
nuclei	O
,	O
based	O
on	O
the	O
use	O
of	O
carbobenzoxy-L-phenylalanine	O
(	O
CBZ-L-phe	O
)	O
to	O
prevent	O
breakdown	O
of	O
hormone-receptor	B-protein
complexes	I-protein
during	O
extraction	O
of	O
nuclei	O
with	O
0.6M	O
KCl	O
.	O
Using	O
this	O
method	O
,	O
specific	O
nuclear	O
glucocorticoid	O
binding	O
was	O
demonstrated	O
in	O
14/14	O
patients	O
with	O
untreated	O
CLL	O
.	O
No	O
correlation	O
was	O
found	O
between	O
levels	O
of	O
nuclear-associated	O
3H-TA	O
and	O
peripheral	O
white	O
blood	O
cell	O
count	O
or	O
rosetting	O
ability	O
of	O
circulating	O
lymphocytes	O
.	O
Multiple	O
closely-linked	O
NFAT/octamer	O
and	O
HMG	O
I	O
(	O
Y	O
)	O
binding	O
sites	O
are	O
part	O
of	O
the	O
interleukin-4	O
promoter	O
.	O
We	O
show	O
here	O
that	O
the	O
immediate	O
upstream	O
region	O
(	O
from	O
position	O
-12	O
to	O
-270	O
)	O
of	O
the	O
murine	O
interleukin	O
4	O
(	O
Il-4	O
)	O
gene	O
harbors	O
a	O
strong	O
cell-type	O
specific	O
transcriptional	O
enhancer	O
.	O
In	O
T	O
lymphoma	O
cells	O
,	O
the	O
activity	O
of	O
the	O
Il-4	O
promoter/enhancer	O
is	O
stimulated	O
by	O
phorbol	O
esters	O
,	O
Ca++	O
ionophores	O
and	O
agonists	O
of	O
protein	B-protein
kinase	I-protein
A	I-protein
and	O
inhibited	O
by	O
low	O
doses	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O
The	O
Il-4	O
promoter/enhancer	O
is	O
transcriptionally	O
inactive	O
in	O
B	O
lymphoma	O
cells	O
and	O
HeLa	O
cells	O
.	O
DNase	O
I	O
footprint	O
protection	O
experiments	O
revealed	O
six	O
sites	O
of	O
the	O
Il-4	O
promoter/enhancer	O
to	O
be	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O
Among	O
them	O
are	O
four	O
purine	O
boxes	O
which	O
have	O
been	O
described	O
to	O
be	O
important	O
sequence	O
motifs	O
of	O
the	O
Il-2	O
promoter	O
.	O
They	O
contain	O
the	O
motif	O
GGAAA	O
and	O
are	O
recognized	O
by	O
the	O
inducible	B-protein
and	I-protein
cyclosporin	I-protein
A-sensitive	I-protein
transcription	I-protein
factor	I-protein
NFAT-1	I-protein
.	O
Three	O
of	O
the	O
Il-4	O
NFAT-1	O
sites	O
are	O
closely	O
linked	O
to	O
weak	O
binding	O
sites	O
of	O
Octamer	B-protein
factors	I-protein
.	O
Several	O
purine	O
boxes	O
and	O
an	O
AT-rich	O
protein-binding	O
site	O
of	O
the	O
Il-4	O
promoter	O
are	O
also	O
recognized	O
by	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
HMG	B-protein
I	I-protein
(	I-protein
Y	I-protein
)	O
.	O
Whereas	O
the	O
binding	O
of	O
NFAT-1	B-protein
and	O
Octamer	B-protein
factors	I-protein
enhance	O
the	O
activity	O
of	O
the	O
Il-4	O
promoter	O
,	O
the	O
binding	O
of	O
HMG	O
I	O
(	O
Y	O
)	O
suppresses	O
its	O
activity	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
involved	O
in	O
the	O
suppression	O
of	O
Il-4	B-protein
transcription	O
in	O
resting	O
T	O
lymphocytes	O
.	O
Reversibility	O
of	O
the	O
differentiated	O
state	O
in	O
somatic	O
cells	O
.	O
Analysis	O
of	O
de	O
novo	O
gene	O
activation	O
in	O
multinucleated	O
heterokaryons	O
has	O
shown	O
that	O
the	O
differentiated	O
state	O
,	O
although	O
stable	O
,	O
is	O
not	O
irreversible	O
,	O
and	O
can	O
be	O
reprogrammed	O
in	O
the	O
presence	O
of	O
appropriate	O
combinations	O
of	O
trans-acting	B-protein
regulatory	I-protein
molecules	I-protein
.	O
These	O
properties	O
have	O
been	O
exploited	O
to	O
design	O
strategies	O
for	O
identifying	O
novel	O
regulators	O
of	O
cellular	O
differentiation	O
.	O
Phosphatidylcholine	O
hydrolysis	O
activates	O
NF-kappa	B-protein
B	I-protein
and	O
increases	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
human	O
monocytes	O
and	O
T	O
lymphocytes	O
.	O
We	O
have	O
tested	O
whether	O
breakdown	O
of	O
phosphatidylcholine	O
(	O
PC	O
)	O
initiated	O
by	O
exogenous	O
addition	O
of	O
a	O
PC-specific	B-protein
phospholipase	I-protein
C	I-protein
(	O
PC-PLC	B-protein
)	O
from	O
Bacillus	O
cereus	O
or	O
by	O
endogenous	O
overexpression	O
of	O
PC-PLC	B-protein
induces	O
functional	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
increases	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
activity	O
.	O
PC-PLC-activated	O
hydrolysis	O
of	O
PC	O
was	O
found	O
to	O
induce	O
bona	O
fide	O
p50/p65	B-protein
NF-kappa	I-protein
B	I-protein
binding	O
activity	O
in	O
three	O
different	O
cell	O
lines	O
of	O
human	O
or	O
murine	O
origin	O
.	O
No	O
significant	O
changes	O
in	O
the	O
turnover	O
of	O
other	O
cellular	O
phospholipids	O
were	O
detected	O
in	O
PC-PLC-treated	O
cells	O
.	O
Induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PC-PLC	B-protein
did	O
not	O
depend	O
on	O
de	O
novo	O
synthesis	O
of	O
proteins	O
or	O
autocrine	O
secretion	O
of	O
either	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
interleukin	B-protein
1	I-protein
.	O
In	O
human	O
monocytic	O
and	O
lymphoblastoid	O
T-cell	O
lines	O
,	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
PC-PLC	B-protein
resulted	O
in	O
clear	O
induction	O
of	O
luciferase	B-protein
expression	O
vectors	O
placed	O
under	O
the	O
control	O
of	O
synthetic	O
kappa	O
B	O
enhancers	O
or	O
wild	O
type	O
,	O
but	O
not	O
kappa	O
B-mutated	O
,	O
HIV	O
long	O
terminal	O
repeat	O
constructs	O
.	O
HIV	O
replication	O
was	O
increased	O
by	O
PC-PLC	B-protein
in	O
chronically	O
infected	O
monocytes	O
and	O
T	O
lymphocytes	O
.	O
NF-kappa	O
B	O
activation	O
promoted	O
by	O
addition	O
of	O
exogenous	B-protein
PC-PLC	I-protein
correlated	O
with	O
an	O
intense	O
production	O
of	O
diacylglycerol	O
.	O
However	O
,	O
addition	O
of	O
a	O
phosphatidylinositol-specific	B-protein
PLC	I-protein
from	O
B.cereus	O
also	O
induced	O
diacylglycerol	O
but	O
did	O
not	O
activate	O
kappa	B-protein
B	I-protein
enhancer-directed	I-protein
vectors	I-protein
.	O
PC-PLC-induced	O
NF-kappa	O
B	O
activation	O
could	O
not	O
be	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
phorbol	B-protein
ester-inducible	I-protein
protein	I-protein
kinases	I-protein
C	I-protein
.	O
These	O
results	O
indicate	O
that	O
a	O
cellular	O
transduction	O
pathway	O
,	O
dependent	O
on	O
specific	O
PC	O
breakdown	O
,	O
is	O
functional	O
in	O
T	O
lymphocytes	O
and	O
monocytes	O
and	O
may	O
be	O
used	O
by	O
various	O
transmembrane	O
receptors	O
to	O
activate	O
HIV	O
transcription	O
through	O
NF-kappa	O
B-dependent	O
induction	O
of	O
the	O
HIV	O
enhancer	O
.	O
Novel	O
mechanism	O
for	O
inhibition	O
of	O
human	O
T	O
cells	O
by	O
glucocorticoids	O
.	O
Glucocorticoids	O
inhibit	O
signal	O
transduction	O
through	O
IL-2	B-protein
receptor	I-protein
.	O
Interaction	O
of	O
IL-2	B-protein
with	O
its	O
high	B-protein
affinity	I-protein
membrane	I-protein
receptor	I-protein
complex	I-protein
(	O
IL-2R	B-protein
)	O
present	O
on	O
activated	O
T	O
lymphocytes	O
induces	O
cell	O
proliferation	O
and	O
mediates	O
effector	O
functions	O
.	O
Glucocorticoids	O
inhibit	O
IL-2	B-protein
production	O
by	O
inhibiting	O
TCR-mediated	O
signal	O
transduction	O
.	O
We	O
asked	O
whether	O
they	O
also	O
inhibit	O
the	O
action	O
of	O
IL-2	B-protein
by	O
inhibiting	O
signal	O
transduction	O
through	O
IL-2R	B-protein
.	O
Human	O
peripheral	O
blood	O
T	O
cells	O
,	O
stimulated	O
with	O
PMA	O
for	O
48	O
h	O
(	O
PMA	O
blasts	O
)	O
,	O
were	O
incubated	O
with	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
incremental	O
dosages	O
of	O
dexamethasone	O
(	O
Dex	O
;	O
10	O
(	O
-5	O
)	O
-10	O
(	O
-9	O
)	O
M	O
)	O
.	O
Dex	O
inhibited	O
the	O
IL-2-dependent	O
proliferation	O
of	O
PMA	O
blasts	O
in	O
a	O
dose-dependent	O
fashion	O
(	O
IC50	O
,	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
)	O
.	O
Cell	O
surface	O
expression	O
of	O
IL-2R	B-protein
alpha-	I-protein
and	I-protein
beta-chains	I-protein
as	O
determined	O
by	O
immunofluorescence	O
analysis	O
was	O
not	O
affected	O
by	O
Dex	O
.	O
In	O
addition	O
,	O
Scatchard	O
plot	O
analysis	O
of	O
125I-labeled	B-protein
IL-2	I-protein
showed	O
that	O
Dex	O
did	O
not	O
affect	O
the	O
binding	O
of	O
IL-2	B-protein
,	O
thus	O
suggesting	O
that	O
inhibition	O
is	O
due	O
to	O
a	O
postreceptor	O
effect	O
.	O
Inhibition	O
of	O
T	O
cell	O
proliferation	O
by	O
Dex	O
was	O
associated	O
with	O
decreased	O
IL-2-dependent	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	B-protein
proteins	I-protein
and	O
decreased	O
phosphorylation	O
of	O
the	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
Rb	I-protein
,	O
a	O
protein	O
essential	O
for	O
controlling	O
the	O
progression	O
of	O
cells	O
through	O
the	O
cell	O
cycle	O
.	O
IL-2-dependent	O
IL-2R	O
alpha	O
expression	O
in	O
PMA	O
blasts	O
and	O
NF-kB	B-protein
induction	O
in	O
resting	O
human	O
T	O
cells	O
were	O
also	O
inhibited	O
by	O
Dex	O
.	O
These	O
results	O
demonstrate	O
that	O
glucocorticoids	O
inhibit	O
preactivated	O
T	O
cells	O
by	O
down-regulating	O
signal	O
transduction	O
through	O
IL-2R	B-protein
.	O
Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
stimulates	O
distinct	O
NF-kappa	O
B/rel	O
DNA	O
binding	O
activities	O
in	O
myelomonoblastic	O
cells	O
.	O
The	O
relationship	O
between	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
the	O
induction	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
was	O
examined	O
in	O
a	O
myeloid	O
cell	O
model	O
of	O
HIV-1	O
infection	O
derived	O
from	O
the	O
PLB-985	O
cell	O
line	O
.	O
Chronic	O
infection	O
of	O
PLB-985	O
cells	O
led	O
to	O
increased	O
monocyte-specific	O
surface	O
marker	O
expression	O
,	O
increased	O
c-fms	O
gene	O
transcription	O
,	O
and	O
morphological	O
alterations	O
consistent	O
with	O
differentiation	O
along	O
the	O
monocytic	O
pathway	O
.	O
PLB-IIIB	O
cells	O
displayed	O
a	O
constitutive	O
NF-kappa	O
B-like	O
binding	O
activity	O
that	O
was	O
distinct	O
from	O
that	O
induced	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
treatment	O
of	O
the	O
parental	O
PLB-985	O
cell	O
line	O
.	O
This	O
unique	O
DNA	O
binding	O
activity	O
consisted	O
of	O
proteins	O
of	O
70	B-protein
,	I-protein
90	I-protein
,	I-protein
and	I-protein
100	I-protein
kDa	I-protein
with	O
a	O
high	O
degree	O
of	O
binding	O
specificity	O
for	O
the	O
NF-kappa	B-protein
B	I-protein
site	I-protein
within	O
the	O
PRDII	B-protein
domain	I-protein
of	O
beta	B-protein
interferon	I-protein
.	O
In	O
this	O
report	O
,	O
we	O
characterize	O
the	O
nature	O
of	O
these	O
proteins	O
and	O
demonstrate	O
that	O
binding	O
of	O
these	O
proteins	O
is	O
also	O
induced	O
following	O
Sendai	O
paramyxovirus	O
infection	O
.	O
The	O
70-kDa	B-protein
protein	I-protein
corresponds	O
to	O
the	O
NF-kappa	B-protein
B	I-protein
RelA	I-protein
(	I-protein
p65	I-protein
)	I-protein
subunit	I-protein
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
an	O
acute	O
paramyxovirus	O
infection	O
or	O
a	O
chronic	O
HIV-1	O
infection	O
.	O
Virus	O
infection	O
does	O
not	O
appear	O
to	O
alter	O
the	O
amount	O
of	O
RelA	B-protein
(	O
p65	B-protein
)	O
or	O
NFKB1	B-protein
(	O
p50	B-protein
)	O
but	O
rather	O
affects	O
the	O
capacity	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
sequester	O
RelA	B-protein
(	I-protein
p65	I-protein
)	I-protein
,	O
therefore	O
leading	O
to	O
constitutive	O
levels	O
of	O
RelA	O
DNA	O
binding	O
activity	O
and	O
to	O
increased	O
levels	O
of	O
NF-kappa	O
B-dependent	O
gene	O
activity	O
.	O
The	O
virally	O
induced	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
have	O
a	O
distinct	O
binding	O
specificity	O
for	O
the	O
PRDII	O
domain	O
and	O
an	O
AT-rich	O
sequence	O
but	O
do	O
not	O
cross-react	O
with	O
NF-kappa	O
B	O
subunit-specific	O
antisera	O
directed	O
against	O
NFKB1	B-protein
(	O
p105	B-protein
or	O
p50	B-protein
)	O
,	O
NFKB2	B-protein
(	O
p100	B-protein
or	O
p52	B-protein
)	O
,	O
RelA	B-protein
(	O
p65	B-protein
)	O
,	O
or	O
c-rel	B-protein
.	O
DNA	O
binding	O
of	O
the	O
90-	B-protein
to	I-protein
100-kDa	I-protein
proteins	I-protein
was	O
not	O
inhibited	O
by	O
recombinant	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
and	O
was	O
resistant	O
to	O
tryptic	O
digestion	O
,	O
suggesting	O
that	O
these	O
proteins	O
may	O
not	O
be	O
NF-kappa	B-protein
B	I-protein
related	I-protein
.	O
Transient	O
cotransfection	O
experiments	O
demonstrated	O
that	O
RelA	O
and	O
NFKB1	O
expression	O
maximally	O
stimulated	O
HIV-1	O
LTR-	O
and	O
NF-kappa	O
B-dependent	O
reporter	O
genes	O
;	O
differences	O
in	O
NF-kappa	O
B-like	O
binding	O
activity	O
were	O
also	O
reflected	O
in	O
higher	O
constitutive	O
levels	O
of	O
NF-kappa	O
B-regulated	O
gene	O
expression	O
in	O
HIV-1-infected	O
myeloid	O
cells	O
.	O
Presence	O
of	O
estrogen-binding	O
sites	O
on	O
macrophage-like	O
synoviocytes	O
and	O
CD8+	O
,	O
CD29+	O
,	O
CD45RO+	O
T	O
lymphocytes	O
in	O
normal	O
and	O
rheumatoid	O
synovium	O
.	O
OBJECTIVE	O
.	O
To	O
study	O
the	O
presence	O
of	O
estrogen-binding	O
sites	O
(	O
EBS	O
)	O
in	O
the	O
synovial	O
tissues	O
of	O
male	O
and	O
female	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
.	O
METHODS	O
.	O
Both	O
type	O
1	O
(	O
high	O
affinity	O
,	O
low	O
binding	O
capacity	O
)	O
and	O
type	O
2	O
(	O
reduced	O
affinity	O
,	O
higher	O
binding	O
capacity	O
)	O
EBS	O
were	O
investigated	O
in	O
both	O
soluble	O
and	O
nuclear	O
fractions	O
of	O
homogenized	O
synovial	O
tissue	O
samples	O
by	O
a	O
dextran-coated	O
charcoal	O
method	O
.	O
To	O
determine	O
what	O
type	O
of	O
synovial	O
cell	O
was	O
positive	O
for	O
EBS	O
,	O
cryosections	O
of	O
synovial	O
tissues	O
were	O
immunostained	O
with	O
a	O
specific	O
monoclonal	B-protein
anti-estrogen	I-protein
receptor	I-protein
antibody	I-protein
(	O
anti-ER	B-protein
MAb	I-protein
)	O
using	O
both	O
immunofluorescence	O
and	O
immunoperoxidase	O
techniques	O
.	O
Double	O
immunostaining	O
with	O
the	O
anti-ER	B-protein
MAb	I-protein
and	O
with	O
specific	B-protein
MAb	I-protein
to	O
detect	O
different	O
macrophage	B-protein
antigens	I-protein
(	O
Ber-MAC3	B-protein
,	O
MAC387	B-protein
,	O
CD68	B-protein
)	O
and	O
CD8+	O
T	O
cell	O
subsets	O
(	O
CD29+	O
,	O
CD45RO+	O
and	O
CD29-	O
,	O
CD45RO-	O
)	O
was	O
performed	O
.	O
RESULTS	O
.	O
Higher	O
affinity	O
EBS	O
were	O
found	O
mostly	O
in	O
nuclear	O
cell	O
fractions	O
of	O
either	O
RA	O
or	O
control	O
synovial	O
tissues	O
(	O
28	O
of	O
the	O
33	O
)	O
.	O
These	O
EBS	O
were	O
present	O
to	O
a	O
lesser	O
extent	O
in	O
soluble	O
cell	O
fractions	O
(	O
11	O
of	O
the	O
33	O
)	O
.	O
Immunostaining	O
showed	O
the	O
estrogen	O
receptor-positive	O
cells	O
to	O
be	O
the	O
macrophage-like	O
synoviocytes	O
and	O
the	O
CD8+	O
,	O
CD29+	O
T	O
cells	O
both	O
in	O
RA	O
and	O
in	O
control	O
synovial	O
tissues	O
.	O
Higher	O
nuclear	O
content	O
of	O
EBS	O
was	O
consistent	O
with	O
more	O
intense	O
nuclear	O
staining	O
of	O
synoviocytes	O
and	O
T	O
cells	O
.	O
CONCLUSION	O
.	O
It	O
is	O
conceivable	O
that	O
the	O
immunomodulatory	O
activity	O
exerted	O
by	O
estrogens	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
their	O
interaction	O
with	O
EBS	O
that	O
are	O
present	O
on	O
macrophage-like	O
synoviocytes	O
,	O
functioning	O
as	O
antigen-processing	O
and	O
antigen-presenting	O
cells	O
,	O
and	O
on	O
antigen-experienced	O
(	O
memory	O
)	O
CD8+	O
T	O
lymphocytes	O
(	O
CD29+	O
,	O
CD45RO+	O
